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Campylobacter is the major bacterial cause of human gastroenteritis in the United 
States and other developed countries. Poultry are considered a main source of human 
Campylobacter infections. Thus, reduction of Campylobacter load in poultry is 
significant in food safety and public health. However, no effective measure is 
commercially available to prevent Campylobacter colonization in poultry to date. 
Antimicrobial peptides (AMPs) are short and bactericidal peptides widely present in 
intestine to limit bacterial infections. Recently, AMPs have been increasingly recognized 
as a novel class of antibiotics (peptide antibiotics) to control foodborne pathogens. 
Notably, several potent anti-Campylobacter bacteriocins, a group of AMPs produced by 
commensal bacteria, dramatically reduced C. jejuni colonization in chickens and are 
being directed toward on-farm control of this pathogen to protect public health. As an 
important strategy to evade killing by potential peptide antibiotics and by host innate 
defense, AMP resistance mechanisms in C. jejuni are critical to understand, but are still 
unknown. In this dissertation, molecular basis of Campylobacter resistance to polymyxin 
B, the anti-Campylobacter bacteriocins (BCNs), and a chicken host defense AMP 
(fowlicidin-1) was comprehensively examined using both in vitro and in vivo systems. 
Although polymyxin B has been successfully used as a model peptide to study AMP 
resistance in other Gram-negative bacteria, functional genomics examination in this study 
suggested that polymyxin B is not a good surrogate to study Campylobacter resistance to 
physiologically relevant AMPs. Campylobacter only developed low-level BCN 
resistance with low frequency in vitro and in vivo; the acquired BCN resistance was not 
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stable in Campylobacter. Genomic examination of two BCN resistant mutants using 
DNA microarray and random transposon mutagenesis revealed that the multidrug efflux 
pump CmeABC contributes to both intrinsic and acquired resistance of Campylobacter to 
the BCNs. Random transposon mutagenesis and targeted site-directed mutagenesis 
identified four genes (cbrR, tig, cjaB, and cj1583c) involved in Campylobacter resistance 
to fowlicidin-1. These genes were also required for optimal colonization of 
Campylobacter in chickens. Together, the findings from this dissertation revealed 
uniqueness and complexity of AMP resistance in Campylobacter and will enable us to 
develop more sustainable peptide antibiotics and novel intervention strategies to prevent 
and control Campylobacter infections in humans and animal reservoirs. 
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Campylobacter has emerged as the leading bacterial cause of human 
gastroenteritis in the United States and other industrialized countries (Ruiz-Palacios 
2007). This pathogenic organism is also associated with Guillain-Bare syndrome, an 
acute flaccid paralysis that may lead to respiratory muscle compromise and death. In the 
United States, the estimated cases of campylobacteriosis are more than 2 million, which 
have resulted in economical and medical costs of 1.5 to 8 billion US dollars each year 
(Buzby et al. 1997). Poultry and their products are the major sources for human 
Campylobacter infections (Kassenborg et al. 2004). In parallel to its increased 
prevalence, Campylobacter has become increasingly resistant to clinical antibiotics, 
posing a serious threat to public health (Allos 2001).  Therefore, development of effective 
intervention strategies is urgently needed to prevent and control Campylobacter 
infections in humans and animal reservoirs.  
Endogenous antimicrobial peptides (AMPs) belong to the most ancient and 
efficient components of host defense. Defensins and cathelicidins are two major groups 
of host AMPs that limit bacterial infections at the gastrointestinal mucosal surface (Bulet 
et al. 2004; Wehkamp et al. 2007). In addition to their significant role in host innate 
defense, AMPs including chicken cathelicidin fowlicidin-1 (F-1) have been increasingly 
recognized as a novel class of antibiotics (peptide antibiotics) to control pathogens (Xiao 
et al. 2006; Bommineni et al. 2007). Given the wide prevalence and successful 
colonization of C. jejuni in intestinal tract, C. jejuni should have acquired mechanisms to 
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resist AMPs widely present in the host. However, as an important strategy to evade 
killing by innate immunity and by potential peptide antibiotics AMP resistance 
mechanisms are still largely unknown in Campylobacter.  Availability of this information 
will provide insights into the delicate host-pathogen interactions and reveal novel 
intervention targets to control Campylobacter infections in humans and animal reservoirs. 
Some commensal bacteria also produce defense peptides, called bacteriocins 
(BCNs), to inhibit growth of other bacteria and gain survival advantage in specific niche 
in intestine (Riley et al. 2002). The natural and low-toxic BCNs have been proposed as 
promising candidates for novel antimicrobials (Cotter et al. 2005). Notably, several anti-
Campylobacter BCNs have been characterized (Stern et al. 2005; Svetoch et al. 2005; 
Stern et al. 2006). These BCNs have displayed potent killing effect against 
Campylobacter and dramatically reduced C. jejuni colonization in the intestine. 
Therefore, these natural anti-Campylobacter BCNs are being directed toward on-farm 
control of Campylobacter (Lin 2009). However, several critical issues of BCN 
applications (e.g. resistance development and mechanism) need to be addressed for future 
regulatory approval and public acceptability of this intervention measure. 
Polymyxin B (PM), a peptide antibiotic, has been used as a model peptide to 
study AMP resistance in many Gram-negative bacteria (Ernst et al. 2001; Finlay et al. 
2004). Gram-negative bacterial pathogens utilize multiple mechanisms to resist killing by 
PMs and other AMPs (Groisman et al. 1997; Ernst et al. 1999; Guina et al. 2000; Ernst et 
al. 2001; Groisman 2001; Lee et al. 2004; Moon et al. 2009). Inactivation of the genes 
responsible for PM resistance usually results in increased susceptibility of bacteria to a 
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variety of innate AMPs, leading to the reduced virulence of the mutants in animal model 
system (Ernst et al. 2001). Thus, investigation of PM resistance should be highly relevant 
to resistance to physiologically relevant AMPs and pathogenesis of Campylobacter. 
The main objective of this project is to examine AMP resistance in 
Campylobacter using both in vitro and in vivo systems. The following specific objectives 
were persued in this dissertation research: 
1) To identify and characterize genes involved in C. jejuni resistance to 
polymyxin B.  
2) To determine the prevalence, development, and molecular mechanisms of BCN 
resistance in Campylobacter. 
3) To determine the in vivo development and stability of BCN resistance in 
Campylobacter using chicken model system. 
4)   To systemically identify genes required for Campylobacter resistance to 













BIOCHEMICAL PROPERTIES AND STRUCTURES  
Antimicrobial peptides (AMPs), short peptides with length ranging from 15 to 50 
amino acid residues, are produced virtually by all classes of lives from prokaryotes to 
human and play an important role in innate immunity due to their potent antimicrobial 
activities against microorganisms (Bulet et al. 2004; De Smet et al. 2005).  Based on the 
sequence and structural analysis, more than 900 AMPs have been predicted and 
characterized to date. AMPs exert killing effects against many microorganisms including 
bacteria, viruses, and fungi. Recently, some AMPs (e.g. defensin, lactoferin, cecropin, 
magainin and melitin) were also found to display anticancer function (Hoskin et al. 
2008). 
AMPs are cationic and amphipathic molecules (Yeaman et al. 2003). Cationic 
characteristic is an important feature of AMPs, which could initiate electrostatic 
interaction of AMPs with negatively charged phospholipid membrane of bacteria and 
many other microorganisms (Shai 1999; Yeaman et al. 2003; Toke 2005). Most AMPs 
have high content of positively charged amino acids such as arginine and lysine rather 
than negatively charged amino acids such as aspartic and glutamic acids. Thus, the 
overall charge of AMPs is usually cationic, ranging from +2 to +9 at physiological pH 
(Yeaman et al. 2003; Bulet et al. 2004; Otvos 2005). Hydrophobicity of antimicrobial 
peptides is determined by the percentage of hydrophobic residues in  peptides (Yeaman et 
al. 2003), which facilitates the interaction of AMPs with hydrophobic regions of 
microbial cell membrane. Increasing hydrophobicity significantly increases the ability of 
AMPs to bind and permeate bacterial membrane (Yeaman et al. 2003). Together, the 
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cationic and amphipathic properties of AMPs are critical for killing microorganisms. 
However,  the amphipathicity of AMPs could cause toxicity to host cells whose 
membrane is composed of neutral phospholipids (Yeaman et al. 2003). Based on the 
sequence and structure analysis, AMPs have been classified into four groups (Oren et al. 
1998; Weinberg et al. 1998):   
(1) Linear α-helical AMPs. This group contains AMPs with simple linear, helical 
structure lacking disulfide bonds. They can be virtually found in many classes of living 
organisms including virus, bacteria, insects, fish, and human (Oren et al. 1998; Tossi et 
al. 2000). For example, cecropins, ceratotoxins, and metilins, which are produced by 
moths, flies, and bees, respectively, all belong to this group (Saito et al. 2005; Brown et 
al. 2008). Despite great differences on the origins, length, charge distribution, and 
hydrophobicity, the AMPs in this group contain positively charged regions and prone to 
adopt alpha helical conformation. Notably, many such AMPs only become alpha helical 
when they  interact with amphipathic phospholipids of cell membrane (Yeaman et al. 
2003).  
(2) Linear α-helical peptides without cystein and with high portion of certain 
amino acid residues such as proline, arginine and tryptophan (Dathe et al. 1999; 
Yeaman et al. 2003). These AMPs with high content of proline, arginine, or triptophan 
have distinctive cyclic structure that typically form extended conformation in aqueous 
solution and more compact in hydrophobic solvents (McCafferty et al. 1996). Many 
proline-rich AMPs have been identified such as apidaecin from honey bee, pyrrocidin 
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from insect, drocins from flies, bac-5 and bac-7 from bovine, and buforin II from frog 
(Bulet et al. 2004). 
(3)  β-sheet AMPs: This group of AMPs is characterized by the β-hairpin 
structure containing disulfide linkages (Weinberg et al. 1998; Reddy et al. 2004). Beta-
sheet AMPs can be isolated from a large numbers of different plants, animals and from 
various tissues such as trachea, intestine, tongue, plasma, and skin (Weinberg et al. 1998; 
Thomma et al. 2002; Higgs et al. 2007). Defensins, the representative of this group found 
in mammals, have three subfamilies sharing common genetic origin including α-
defensins, β-defensins, and ө-defensins. All of these mammalian defensins are small 
molecules (18–45 residues) that are cysteine and arginine-rich, and have a predominantly 
β-sheet structure that is stabilized by three intramolecular disulfide bonds (Sugiarto et al. 
2004).   
 (4) Cysteine-rich peptides. This group of AMPs contains several cysteine 
residues near C-terminal and N-terminal facilitating intramolecular disulfide bonds 
(Weinberg et al. 1998). For example, human neutrophil HNP-1, -2, and -3 from human 
granules (Ganz et al. 1985), drosomocin from drosophila, bacternectin from bovine 
neutrophill, brevinins and esculetin from frog skin (Ganz et al. 1985; Weinberg et al. 
1998) have three to four disulfide bonds making up complex structure containing alpha 
and anti-parallel beta sheets (Reddy et al. 2004). 
  MODES OF ACTION  
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 AMPs have very diverse sequence composition, conformation structures, and 
biophysical characteristics. The modes of action of AMPs are not fully understood. 
However, it has been widely accepted that AMPs exert antimicrobial activities through 
their interactions with the target membrane and interfering with the intracellular 
components of the microorganisms (Park et al. 1998; Shai 1999; Reddy et al. 2004; Otvos 
2005; Brown et al. 2006; Meade et al. 2009). 
Bacterial membrane targets. Fundamental differences between the mammalian 
cell membrane and bacterial cell membrane are the constituent compositions and 
architectures of the cell membrane. The normal mammalian cell membrane lipid bilayer 
is composed of neutrally charged lipid such as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), and sphingo myline (SM).  However, the lipid bilayers 
of bacterial cell membrane consist of positively charged components such as 
phosphatidylglycerol (PG), phosphatidylserine (PS), and cardiolipin (Yeaman et al. 
2003). The surface peptidoglycan is also negatively charged with the presence of techoic 
or terichuronic acids. In addition, Gram-negative bacteria have outer membrane 
composed of lipopolysaccharides (LPS) with negatively charged constituents such as 
phosphate group. These features make bacterial cell membrane have higher overall 
negative charge than normal mammalian cell membrane. Therefore, the negative charge 
together with the amphipathic feature of bacterial cell membrane facilitates the direct 
interaction between AMPs and bacterial envelope. 
AMPs interact with bacterial cell membrane via electrostatic and/or hydrophobic 
interactions. Briefly, cationic AMPs contact with negatively charged phosphate lipid 
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group of membrane via electrostatic force. Following this process is the interaction of 
hydrophobic domains of AMPs with hydrophobic groups of lipid chains in membrane. 
These interactions facilitate the AMP structure transit to favorable conformation, leading 
to the membrane pore formation, following by permeation, and transfer of AMPs into the 
cells. Three models of bacterial cell membrane pore formation have been proposed 
including barrel-stave mechanism, carpet-like mechanism, and toroidal pore mechanism 
(Oren et al. 1998; Park et al. 1998; Shai 1999; Yeaman et al. 2003; Bulet et al. 2004; 
Sengupta et al. 2008). Although AMPs commonly interact with bacterial cell membrane 
without requirement of AMP specific receptor, recent research demonstrated that some 
AMPs interact with bacterial cell membrane through specific receptors. For example, 
some AMPs, such as nisin, could target on lipid II, the precursor required for membrane 
peptidoglycan synthesis during cell division, and cause cell death (Hasper et al. 2004). 
Intracellular targets. The membrane perturbation of AMPs has been widely 
examined and is a major mechanism of AMP actions. However, there is increasing 
evidence to prove that AMPs have intracellular targets (Kragol et al. 2001; Xiong et al. 
2002; Yeaman et al. 2003; Otvos 2005; Pujals et al. 2008; Cho et al. 2009). Some AMPs 
could inhibit DNA replication. For instance, buforin II directly binds to DNA (Cho et al. 
2009). Thrombin-induced palette protein tPMP-1, human neutrophil defensin HNP-1, and 
bacterial peptide microcin B17 have been reported to interfere with DNA gyrase, an 
essential  enzyme for  relaxing the DNA scaffold during DNA replication (Xiong et al. 
1999; Heddle et al. 2001; Otvos 2005; Cho et al. 2009). Demaseptin, a chiramic peptide, 
could inhibit RNA synthesis (Balaban et al. 2004). Several AMPs also interfere with 
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protein translation and functions. For example, tPMP-1 binds to both 30S and 50S 
ribosomal subunits while HNP-1 only binds to 50S subunit (Xiong et al. 1999); proline-
rich peptides pyrrhocoricin, drocin, and apidaecin could interact with bacterial heat shock 
protein DnaK, an important protein responsible for protein folding (Kragol et al. 2001). 
Human histatins have high affinity to fungi mitochondrion and inhibit respiration process 
(Helmerhorst et al. 1999). However, the mechanisms of translocation of AMPs from 
surface to cytoplasm are not fully understood. It is important to note that a single AMP 
may have multiple surface as well as intracellular targets. 
AVIAN ANTIMICROBIAL PEPTIDES  
Recently, a full panel of avian AMPs have been identified and characterized from 
chicken, turkey, penguin, and mallard duck (Sugiarto et al. 2004; Lynn et al. 2007). 
Based on their sequences and structures, these AMPs fall into two groups, β- sheet  and 
α-helical known as β-defensins and fowlicidins respectively (van Dijk et al. 2005; Lynn 
et al. 2007). 
  β-defensins are cystein-rich with a triple-stranded β-sheet structure connected by 
a loop of  β-hairpin and are evolutionary conserved in humans and various animals 
(Sugiarto et al. 2004). Avian β-defensins (AvBDs), produced by heterophils and 
epithelial cells also called ‘gallinacins’ in chicken, include 14 homologous peptides 
encoded by cluster of genes located on chromosome 3 (Xiao et al. 2004; Lynn et al. 
2007). Avian heterophil β-defensins include Gal -1, Gal-1α, Gal-2 isolated from chicken; 
THP-1, THP-2 isolated from turkey; Osp-1 isolated from ostrich (Sugiarto et al. 2004; 
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Lynn et al. 2007). Avian non-heterophil β-defensins are produced by epithelial cells at 
different locations in the body. Chicken Gal-3 and turkey GVP-1 both containing 39 
amino acid residues and are produced by tracheal epithelial cells (Zhao et al. 2001). 
Penguin sphenicin was isolated from stomach content of penguin (Thouzeau et al. 2003). 
Gal-3 was also expressed in large intestine, air sac esophagus, skin, bursa  of fabricius, 
and kidney (Sugiarto et al. 2004). Different avian β-defensins and nomenclatures are 
summarized in Table 1. 
Fowlicidin family consists of four members including CTHL-1, CTHL-2, CTHL-
3 and CTHL-B1 encoded by cluster of genes located on chromosome 2 (van Dijk et al. 
2005; Xiao et al. 2006). Phylogenetic analysis demonstrated that CTHL-1, CTHL-2, and 
CTHL-3 are expressed by heteotrophil while CTHLB1 is expressed by mucosal epithelial 
M cells (van Dijk et al. 2005; Xiao et al. 2006). 
Avian AMPs could be constitutively expressed under normal  physiological 
conditions to resist microbial infections (Meade et al. 2009). Some chicken AMPs are 
expressed at different levels at different locations during early period of embryo 
development. Avian β-defensins 9, 10 were highly expressed at day 10 and day 12 in 
embryo abdomen while β- defensin 14 was highly expressed in the head of embryo 
(Meade et al. 2009). Avian defensins were found to be expressed in liver, intestine, and 
reproductive tracts (Silphaduang et al. 2006; Li et al. 2007; van Dijk et al. 2007). The 
expression of avian AMPs increases upon microbial infection. The β-defensin 1, 2, 4, 6 
and fowlicidins were highly expressed in chicken infected with Salmonella enterica 
serova Typhimurium (Akbari et al. 2008). 
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AMPs play an important role in innate and specific immune response. The 
antimicrobial activities are more important in avian than mammals because avian 
heterophils lack superoxide ion and myeloperoxidase (Penniall et al. 1975; Sugiarto et al. 
2004). Avian AMPs have a wide range of antimicrobial activities against Gram-negative, 
Gram-positive bacteria, and fungi (Sugiarto et al. 2004). Chicken heterophil β- defensin 
Gal-1, Gal-1α, and Gal-2 displayed antimicrobial activities against E. coli and Listeria 
monocytogenes; turkey defensins have broader antimicrobial spectrum  against various 
pathogens including Mycoplasma and fungi (Sugiarto et al. 2004). Antimicrobial 
activities of fowlicidins have been well studied. CTHL-1, and 2 display potent and broad 
antimicrobial activities against both Gram-negative and Gram-positive bacteria including 
those with antibiotic resistance (Xiao et al. 2006). These fowlicidins also have ability to 
neutralize bacterial LPS, and consequently reduce inflammation response (Xiao et al. 
2006). However, at high concentration, these fowlicidins exert cytotoxicity toward 
mammalian erythocytes and epithelial cells (Xiao et al. 2006). 
BACTERIOCINS: STRUCTURE AND CLASSIFICATION 
Development and spread of antibiotic resistance in bacterial pathogens have been 
the driving force for scientists to seek antibiotic alternatives. Great attention has been 
focused on bacteriophages, probiotics, and antimicrobial peptides including bacteriocins 
(Asaduzzaman et al. 2009; Lin et al. 2009). Bacteriocins (BCNs) are ribosomally 
synthesized bacterial proteins or peptides with narrow or broad antimicrobial activity 
spectrum against other bacteria. BCNs are produced by both Gram-negative and Gram-
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positive bacteria and up to 99% of bacteria may make at least one BCN for their 
microbial defense system (Klaenhammer 1988; Riley et al. 2002). 
 BCNs have a large degree of structural and biochemical diversity. Although a 
large numbers of bacteriocins have been identified and characterized, new BCNs are still 
being discovered and documented. Based on the physiochemical properties, BCNs have 
been classified into the following classes: 
  Class I bacteriocin (also named ‘lantibiotics’). Lantibiotics are ribosomally 
synthesized peptides containing unusual amino acid lanthionine produced by Gram-
positive bacteria  (Willey et al. 2007). To date, about 50 lantibiotics with average size of 
19-38 amino acid residues have been identified and characterized. To synthesize 
lantibiotics, the prepeptides of lantibiotic undergo extensive posttranslational 
modifications (e.g., dehydration of Ser and Thr), followed by the intramolecular addition 
of Cys residue onto the modified unsaturated amino acid residues (Willey et al. 2007; 
Smith et al. 2008). More than 15 different posttranslational modifications have been 
found in lantibiotics. The different posttranslational modifications result in structurally 
diverse peptides derived  from the same original pre-peptide sequences (Willey et al. 
2007).   
 Class II bacteriocins. Class II BCNs are the heat stable peptides with molecular 
weight less than 10 kDa, and do not contain lanthionine as observed in Class I BCNs. 
They have not undergone posttranslational modifications (Cotter et al. 2005). Based on 
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the structure, antimicrobial activities, and amino acid composition, class II BCNs have 
been divided into following three groups. 
Class IIa bacteriocins. More than 25 different class IIa BCNs with size ranging 
from 37 to 48 amino acid residues have been characterized (Drider et al. 2006). The most 
important characteristic of class IIa BCNs is that cysteine residues are usually located at 
N-terminal and C-terminal that form disulfide-bridge and stabilize their structure. The 
BCNs with higher numbers of disulfide bridges seem to have greater antimicrobial 
activities in comparison with those having  less disulfide bonds (Eijsink et al. 1998). 
Class IIa BCN consists of an N-terminal β-sheet-like domain that is stabilized by the 
conserved disulfide bridge and a C-terminal domain consisting of one or two α-helices of 
which the central α-helix is usually hydrophilic and the C-terminal  α-helix is 
hydrophobic/amphipathic (Fimland et al. 2005). Most of BCNs in this group have 
extended C-terminal tail structure containing an additional sulfide bridge to stabilize the 
3-D structure. N-terminal β-sheet-like domain contains the conserved YGNGVXaaC β-
turn motif. This conformation gives N-terminal of class II bacteriocins amphiphilic 
characteristics (Fimland et al. 2005). It has been suggested that YGNGVXaaC β-turn 
motif is a recognition sequence for membrane receptor which allows correct positioning 
of the BCN in the membrane surface (Chen et al. 1997). Previous studies have supported 
that the changes in YGNGVXaaC motif could lead  to the change of the N-terminal β-
sheet-like domain, ultimately affecting the antibacterial activities of class IIa BCNs 
(Quadri et al. 1997). Furthermore, most positively charged residues are located in the N-
terminal of the peptides. Thus, they are of importance for the initiation of electrostatic 
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interaction with the cell membrane (Chen et al. 1997). The central hydrophilic or slightly 
amphipathic α-helix is believed to have oblique orientation creating 30-600 with cell 
interface when class IIa bacteriocin interacts with bacterial membrane. During the 
interaction, central hydrophilic α- helix interacts with hydrophilic part of the cell 
membrane and spans onto membrane but does not inserts. This interaction facilitates the 
insertion of the C-terminal α- helix into the cell membrane (Bhugaloo-Vial et al. 1996). 
The C-terminal hydrophobic/amphiphilic α-helix also plays a very important role in class 
IIa bactriocin modes of action. It is believed that C-terminal hydrophobic/amphiphilic α-
helix is a putative transmembrane helix and inserts into bacterial cell membrane with the 
help of upstream oblique α-helix to form “barrel-stave” (Bhugaloo-Vial et al. 1996). 
Class IIb bacteriocins are the BCNs containing two peptides that form a 
bacteriocin. To date, about 15 two-peptide bacteriocins have been identified and 
characterized (Nissen-Meyer et al. 2010). A peptide (15-30 residues) from a two-peptide 
bacteriocin displays high antimicrobial activity only when it is combined with a 
complementary peptide. It has been proposed that the bacteriocins form a membrane-
penetrating helix-helix structure involving helix-helix-interacting GxxxG-motifs that are 
present in all characterized two peptide bacteriocins. The membrane and two-peptide 
bacteriocin interaction results in membrane pore formation that renders the membrane of 
sensitive bacteria permeable to a specific group of ions (Nissen-Meyer et al. 2010). 
Class IIc bacteriocins consist of BCNs whose N- and C-terminals are covalently 
linked, forming cyclic structure. Most BCNs of class IIc BCNs contain D-amino acids 
and the mechanisms of action of this bacteriocin group are not been well understood. 
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However, there is evidence that the bacteriocins exert killing bacteria via increased 
potassium ion efflux  (Kawai et al. 2004). 
 Class III bacteriocins. This group of BCNs also named ‘bacteriolysins’ (Cotter 
et al. 2005) are large and heat-labile AMPs with different domains responsible for 
different functions such as translocation, receptor binding, and killing activity (Cotter et 
al. 2005). Less than 10 class III BCNs have been identified and characterized including 
those from non-lactic acid bacteria (Cotter et al. 2005). The mode of action of this group 
of BCNs is different from class I and class II BCNs. They display antimicrobial activities 
toward sensitive cells by catalyzing cell wall hydrolysis (Cotter et al. 2005). For this 
group of BCNs, N-terminal domain is a catalytic domain homologous to endopeptidase 
while C-terminal domain is responsible for recognizing the targets (Valdes-Stauber et al. 
1994; Lai et al. 2002; Johnsen et al. 2005). 
GENETIC ORGANIZATION OF BACTERIOCIN SYNTHESIS 
The genes involved in BCN synthesis are generally found in clusters which can be 
located on bacterial chromosomes or on plasmids (Peschel et al. 2006; Willey et al. 2007; 
Asaduzzaman et al. 2009).  The  class I BCN producers have a panel of genes involved in 
BCN synthesis, which typically consist of genes encoding pre-peptide, posttranslational 
modification enzymes, transporters, accessory proteins, immunity proteins, and regulator. 




The structural gene encoding pre-peptide consists of N-terminal leader sequence 
and the BCN peptide sequence. The leader sequence contains two glycine residues which 
are believed to serve as signal recognition motif for the maturation and membrane 
translocation of the peptide across membrane. BCN transport system includes two 
distinct proteins: an ABC transporter consisting of 2-3 subunits located on the cell 
membrane, and an accessory protein. ABC translocator protein has conserved ATP-
binding domain at C-terminal and hydrophobic integral membrane N-terminal domain 
which was shown to cleave off the leader peptide sequence at double glycine motif. C-
terminal cytosolic domain contains the ATP-binding cassette which, upon binding to 
peptide, triggers ATP hydrolysis, consequently changing the ABC conformation leading 
to pre-peptide removal and translocation across the cytoplasmic membrane (Havarstein et 
al. 1995). It is suggested that the recognition between the N-terminal proteolytic domain 
of ABC transporter and the immature BCNs occurs by the interactions between 
hydrophobic residues on the amphiphilic α-helix pre-sequence and hydrophobic residues 
on or near the catalytic site in the N-terminal proteolytic domain of the ABC transporter 
protein (Aucher et al. 2005). Accessory protein bearing a hydrophobic N-terminal region 
and a large hydrophilic C-terminal section is postulated to be involved in processing 
membrane translocation and helping cleaving off peptide leader sequence (Havarstein et 
al. 1995).  
The BCN-producers use two distinct mechanisms to protect themselves from 
killing by the BCNs produced by themselves, production of immunity protein and 
specific ABC transporter. The ABC membrane efflux transporters are encoded by genes 
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adjacent to BCN synthesis genes. Different class bacteriocin producers use different 
protective strategies. Class I bacteriocin producers use both immunity protein and ABC 
type transporter, meanwhile class IIa and IIb producers use only immunity proteins, and 
class IIc producers rely only on ABC type transporter (Cotter et al. 2005; Stein et al. 
2005). Immunity proteins  are highly charged cytosolic proteins associated with cell 
membrane (Dayem et al. 1996). Immunity proteins interact with specific membrane 
proteins to confer resistance to cognate BCN products (Ennahar et al. 2000; Vincent et al. 
2009). Immunity proteins display high specificity towards their BCNs and exert 
protection only against their cognate BCNs, or under rare situations, against one or two 
other closely related BCNs (Fimland et al. 2002). 
REGULATION OF BACTERIOCIN SYNTHESIS 
Bacteriocin synthesis has long been proven to be regulated by quorum-sensing 
mechanism which includes production of autoinducer and the corresponding two-
component regulatory systems (Quadri 2002; Sturme et al. 2002). In particular, the 
regulation of class II and III BCN synthesis by quorum sensing has been extensively 
studied (Quadri 2002; Riley et al. 2002; Stein et al. 2002). The regulatory system is 
composed of three gene products, also termed three–component regulatory system which 
consists of an autoinducer peptide-pheromone (AIP), a transmembrane histidine kinase 
(pheromone receptor), and a cytoplasmic response regulator (Drider et al. 2006). Similar 
to  the BCN structural genes, the genes encoding for autoinducers have two parts: the 
leader sequence and inductive sequence (Ennahar et al. 2000). The processing of 
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immature inductive peptide including cleavage of leader sequence and membrane 
translocation is similar to the process of BCN maturation and export (Ennahar et al. 
2000). Once outside the cell, induction peptides act as autoinducers for quorum sensing 
to regulate BCN synthesis. In addition to depending on cell density, production of class II 
and III BCNs is affected by temperature, ionic strength, and pH (Leroy et al. 1999; 
Fimland et al. 2000). Class I BCN producers do not have specific autoinducer genes in 
BCN synthesis cluster. Interestingly, some class I BCNs also could function as an 
autoinducer in addition to antibacterial activity. For example, Nisin A has unique 
sequences at N- and C-terminal that serve as quorum sensing signal to interact with its 
corresponding two-component regulatory systems (Miller et al. 2001; Quadri 2002; 
Sturme et al. 2002). However, some evidence suggests that class I bacteriocin producers 
also have other autoinducer genes separating from bacteriocin synthesis cluster genes 
(Sturme et al. 2002). 
APPLICATION OF BACTERIOCINS 
BCNs have been widely used in food processing and preservation (Cotter et al. 
2005; Drider et al. 2006). Recently, BCNs have been increasingly recognized as novel 
antibiotic alternatives to clinical antibiotics to control pathogens (Ennahar et al. 2000; 
Drider et al. 2006). Following are brief reviews for the application of BCNs in different 
areas. 
For decades, BCNs have been used in food processing and preservation. Most 
BCNs are produced by food-grade microorganisms such as lactic acid bacteria (LAB). In 
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addition, most BCNs are heat and pH stable, low toxicity to eukaryotic cells and resistant 
to digestive protease (Cotter et al. 2005; Drider et al. 2006). Thus, application of BCNs in 
food processing and preservation have benefits such as extended shelf life of foods, 
reducing risks of foodborne pathogen transmission and reducing chemical use as 
preservatives (Settanni et al. 2008). Bacteriocins have been applied in food to either 
control the microbial succession during fermentation or inhibiting the uncontrolled 
growth of bacterial spoilage during storage of both animal and vegetable products 
(Aymerich et al. 2002; Settanni et al. 2008). For example, nisin A and Z have been 
accepted worldwide as powerful and safe food additives in controlling food spoilage in 
almost 50 countries for over 40 years (Asaduzzaman et al. 2009). Inoculation of a 
leucocin, a BCN produced by Leuconostoc gelidum, to meat can preserve vacuum-packed 
meat up to 8 weeks by inhibiting the growth of Lactobacillus sakei which spoils meat and 
generates distinct sulfur odors (Leisner et al. 1996). 
Food-borne pathogens are still major problem throughout the world. The leading 
human pathogens associated with foods include Campylobacter spp, Salmonella spp, E. 
coli spp, and Listeria spp. One potential advantage of BCNs or their producer organisms 
is their ability to inhibit the growth or kill foodborne pathogens (Drider et al. 2006). On-
farm control of food borne pathogens is a major concern in the food chain due to the high 
probability of pathogens originating from farms. For example, human 
campylobacateriosis is mostly due the consumption of contaminated poultry meat in 
which Campylobacter colonize commensally. Reduction of Campylobacter spp on farms 
would significantly reduce Campylobacter in meat, and thus reduce human 
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Campylobacter infections (Lin et al. 2009). Several anti-Campylobacter BCNs were 
successfully isolated and characterized from chicken commensal bacteria, which include 
OR-7 from Lactobacillus salivarius (Stern et al. 2006), E-760 and E50-52 from 
Enterococcus faecium (Line et al. 2008; Svetoch et al. 2008), and SRCAM from 
Paenibacillus polymyxa (Stern et al. 2005). Animal studies have demonstrated that these 
BCNs dramatically reduced C. jejuni colonization in chicken intestine and these 
bacteriocins are being developed toward on-farm control of Campylobacter to protect 
public health (Stern et al. 2005; Cole et al. 2006; Svetoch et al. 2008; Lin et al. 2009). 
BCNs and BCN-producers have been also used to control food borne pathogens 
during food processing. For example, supplementation of class IIa bacteriocin producing 
LAB to fresh and processed meat resulted in  temperature-dependent inhibition of the 
growth of Listeria monocytogenesis and Listeria innocua  (Hugas et al. 1998). Addition 
of purified piscicolin 126 and enterocin CCM4231 to cheese and soy milk during 
processing inhibits the growth of L. monocytogenesis (Wan et al. 1997; Laukova et al. 
1999). Also addition of piscicolin 126 to ham paste resulted in reduction of L. 
monocytogenesis below detectable levels (Jack et al. 1996). Recently, a number of BCNs 
isolated from different bacterial strains display antimicrobial activity against L. 
monocytogenesis and could be used to control this food borne pathogen in food products 
(Drider et al. 2006). BCNs can be used in combination with other methods which will 
increase the antimicrobial activity and efficiency of BCNs. These methods include 
chemical substances, pulse electric field, heat treatment, hydrostatic pressure, modified 
atmosphere packaging, and irradiation (Galvez et al. 2007) 
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The rapid development and spread of multi-drug resistance to traditional 
antibiotics are the driving force for seeking alternative methods for infection treatment 
and prevention (Davies 1997). In addition, the biggest limitation of conventional 
antibiotics is their broad spectrum of activities which kill not only targeted bacteria but 
also untargeted microorganisms in various environmental and host niches. Thus, frequent 
use of those antibiotics results in intense selection pressure on sensitive microorganisms 
in the ecosystem (Walker et al. 2001). The current attempt to solve this problem, perhaps, 
is to develop new antibiotics that have narrow spectrum of activity, least likely to 
facilitate resistance, and can combat multi-drug resistant bacteria. Given its narrow 
killing spectrum and diverse modes of action, BCN is a novel and effective alternative to 
conventional antibiotics. The use of BCNs in human and veterinary medicine is still in 
the preclinical stages (Breukink et al. 2006). In vivo trials with animal models have 
demonstrated the success of bacteriocins in treating infections caused by S. pneumonia, 
and multi drug resistant Staphylococcus aureus (Goldstein et al. 1998; Kruszewska et al. 
2004). Nisin, lacticin 3147, mersacin, and actagardine have been demonstrated to be 
effective against bacterial mastitis, oral decay, enterococcal infection, and septic ulcer 
(DelvesBroughton et al. 1996; Goldstein et al. 1998; Galvin et al. 1999). 
THE ROLE OF ANTIMICROBIAL PEPTIDES IN INNATE IMMUNITY AND 
GASTROINTESTINAL INFECTION 
Antimicrobial peptides (AMPs) are a major component of host innate immunity 
systems (Mallow et al. 1996; Bals et al. 2003; Bevins 2005; De Smet et al. 2005; 
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Hasenstein et al. 2006). Defensins and cathelicidins (α-helical AMPs) are two major 
families of AMPs in humans and animals (Wehkamp et al. 2007). Defensins are broadly 
present in mammalian epithelial cells and phagocytes with concentrations as high as 
millimolar levels. Cathelicidins are present in the granules of phagocytes and mucosal 
epithelial cells (Wehkamp, J., J. Schauber, and E. F. Stange. 2007. In the human 
intestinal tract both defensins and cathelicidins are important AMPs expressed by the 
gastrointestinal epithelium and protect host against pathogens (Wehkamp 2007). α-
defensins and β-defensins exert potent killing effect against various pathogens such as  E. 
coli, Staphylococcus aureus, Salmonella enteritica typhimurium, Pseudomonas 
aeruginosa, Listeria monocytogenes ,and fungus Candida albicans (Porter et al. 1997; 
Ghosh et al. 2002). The widespread expression of defensins in the GI tract suggests their 
important role in the maintenance of a stable microbial population in the intestine. This 
could, on the one hand, prevent invasion of host tissues by luminal flora and ingested 
pathogenic bacteria, and on the other hand, maintain relative sterility in certain areas of 
GI tract (Cunliffe et al. 2004). Mice lacking defensins were found to be sensitive to lethal 
infection with S. enteritica serovar Typhimurium, but transgenic mice that expressed 
human defensins could resist oral infection with S. enteritica serovar Typhimurium at 
dose lethal to nontransgenic animal control (Salzman et al. 2003). Moreover, in wild type 
mice the antimicrobial activity was largely neutralized by defensin-specific antibodies, 
indicating that defensins were responsible for most of the activity. Taken together, these 
experiments provided important evidence for the protective role of defensins in the early 
stage of infection. Several studies also demonstrated that defensins take part in adaptive 
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immunity by acting as chemo-attractants for dendritic cells (DCs), monocytes, and T cells 
(Durr et al. 2002). 
Cathelicidins are widely expressed in various tissues including myeloid cells, 
mucosal surface of skin, respiratory epithelia, GI tract, reproductive tract, eccrine and 
salivary glands (Zanetti 2005). Cathelicidins display antimicrobial activities against many 
microorganisms including Gram-negative bacteria  such as P. aeruginosa, S. 
typhimurium, E. coli and Gram-positive bacteria such as S. aureus and S. epidermidis 
(Smeianov et al. 2000). Cathelicidins-deficient mice developed much larger areas of 
subcutaneous infection with Group A Streptococcus than heterozygous or wild type mice 
(Nizet et al. 2001). Other effects of cathelicidin (LL-37) to the innate immune response is 
the ability to bind and neutralize the biological activities of LPS, a septic shock 
component of gram negative bacteria (Larrick et al. 1995). Recruitment of immune cells 
to the site of infection is one process in the innate and adaptive defense. Cathelicidins are 
chemotactic for neutrophils, monocytes, mast cells, and T-cells. In addition, they induce 
degranulation of mast cells, alter transcriptional responses in macrophage, stimulate 
wound vascularization and re-epithelialization of the healing skin, and antitumor 
activities (Okumura et al. 2004; Zanetti 2004). 
Other host AMPs such as histatins and lysozyme that are produced by mammalian 
parotid glands also play an important role in innate immunity. Histatins have 
antimicrobial activity against pathogenic fungi such as Candida albicans, Cryptococcus 
neoformans, and Aspergillus fumigatus (Helmerhorst et al. 1999). Histatins can bind to a 
receptor and enter the cell, leading to cell cycle arrest, efflux of ATP out of the cell, and 
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release of the reactive oxygen radicals (Kavanagh et al. 2004). Lysozyme displays 
bactericidal activity by hydrolyzing β1-4 glycosidic bonds between N-acetyl glucosamine 
and N-acetyl muramic acid of Gram-positive bacterial cell wall and subsequently causes 
cell death. Lysozyme is active against Enterococcus faecalis and Staphylococcus aureus 
(Dommett et al. 2005). Moreover, lysozyme is also able to enhance the phagocytic 
activity of both polymorphonuclear leukocytes and macrophages and bind to free LPS 
and lipoteichoic acid of Gram-negative and Gram-positive bacteria respectively 
(Kokoshis et al. 1978; Ginsburg 2002). PLA2, cytokine CCL20 expressed in GI tract, has 
strong antimicrobial activity against a variety of microorganisms such as Salmonella, E. 
coli, Listeria, and C. albicans (Beers et al. 2002; Yang et al. 2003). Taken together, 
AMPs play indispensible roles in innate immunity in gastrointestinal tracts. 
ANTIMICROBIAL PEPTIDE RESISTANCE IN GRAM-NEGATIVE BACTERIA 
Bacterial pathogens have co-evolved with host innate defense and developed 
means to curtail the effects of endogenous AMPs such as defensins, cathelicidins and 
bacteriocins (Riley et al. 2002; Peschel et al. 2006). The best studied AMP resistance 
mechanisms in Gram-negative bacteria involve 1) electrostatic repulsion of AMPs by 
modification of cell surface, 2) proteolytic cleavage of AMPs, and 3) active extrusion of 
AMPs by drug efflux pumps (Guo et al. 1998; Yeaman et al. 2003; Campos et al. 2004). 
Other mechanisms, such as capsule production, changes in the composition of lipid fatty 
acids in membrane and maintenance of appropriate membrane potential have also been 
implicated in AMP resistance (Campos et al. 2004). Gram-negative bacteria capable of 
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surviving exposure to AMPs utilize two distinct strategies: constitutive resistance and 
inducible resistance (Guo et al. 1998; Yeaman et al. 2003; Yount et al. 2005). These two 
strategies are briefly reviewed below. 
Constitutive mechanisms of resistance are defined as intrinsic or inherent 
properties of bacteria that confer basal level of AMP resistance and are constitutively 
expressed. In general, there are five mechanisms contributing to constitutive resistance to 
AMPs:  1) Inherent cell wall composition or architecture. Most AMPs interact with 
bacterial cell wall which is composed of glycocalyx or phospholipids. Thus, bacteria 
possessing unusual glycocalyx or phospholipid composition inherently may lack 
electrostatic affinity or even repel cationic AMPs, leading to significant intrinsic AMP 
resistance (Yount et al. 2005). 2) Influence of transmembrane potential. Transmembrane 
potential is electrochemical gradient between inner and outer bilayers of the cytoplasmic 
membrane, resulting from differing degrees and rates of proton flux across the 
membrane. This significant difference in membrane electrochemistry has been postulated 
to be crucial in defining selective toxicity of AMPs through self-promoted uptake 
mechanism (Hancock 1997). Transmembrane potential or proton motive force of 
energized membrane facilitates the interaction with antimicrobial peptides. Thus, 
reduction in transmembrane potential may help bacteria resistance to AMPs (Yeaman et 
al. 1998). 3) Electrostatic shielding. Capsule,  glycocalyx or biofilm of certain bacteria 
containing an anionic complex of carbon hydrate and phosphate including anionic acid 
alginate plays very important role in adherence of bacteria to the target cells and helping 
them to avoid opsonic phagocytes (Campos et al. 2004; Bishop et al. 2008). In vitro study 
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showed that the cationic peptides are more antagonized by polyanion alginate (Friedrich 
et al. 1999). Capsule of some bacterial pathogens such as P. aeruginosa, E. coli, 
Klebsiella has been demonstrated to have electronegative alginate which is thought to 
sequester cationic antimicrobial peptides, consequently preclude peptide access to the 
bacterial membrane (Chan et al. 2004). 4) Multidrug efflux pumps. There three major 
families  of multidrug efflux pumps have been characterized in Gram-negative bacteria, 
which include the Major Facilator Superfamily (MFS), the ATP-binding cassette (ABC) 
superfamily, and the Resistance Nodulation Division (RND) family (Piddock 2006). The 
constitutively expressed efflux pumps have been demonstrated to play a role in resistance 
to AMPs such as protamine and human β-defensins (Lin et al. 2002; Moskowitz et al. 
2004; Eswarappa et al. 2008). 5) Niche-specific resistance. In certain anatomical and 
physiological niches, bacteria can resist killing by AMPs due to the  expression of 
specific components in specific niches (Yeaman et al. 2003). Some bacteria have 
potential to exploit specific anatomical settings as a means of circumventing the effect of 
antimicrobial peptides. For instance, opportunistic Gram-negative bacterium P. 
aruginosa preferentially colonizes tissues such as respiratory airway, the mucosal surface 
having abnormal osmotic or ionic strength. The lipid A structures in cystic fibrosis 
(airways) clinical isolates that are more resistant to antimicrobial peptides are distinct 
from those seen in acute clinical infections and isolates from environments (Ernst et al. 




With respect to inducible AMP resistance mechanism that is triggered by 
environmental signals, modifications of LPS in outer membrane via two-component 
regulatory systems (e.g. PhoP/PhoQ) have been identified as major mechanisms to APMs 
in Gram-negative bacteria (Guo et al. 1998; Yount et al. 2005). The negatively charged 
LPS involves the electrostatic interaction of cell surface with cationic AMPs in Gram-
negative bacteria. Thus, Gram-negative bacteria can add covalent modification to LPS 
and consequently reduce the negative charge and/or membrane fluidity of LPS and 
protect themselves from attacks by AMPs.  AMP resistance mediated by LPS 
modifications has been well studied in Salmonella typhimurium (Gunn et al. 1996; Guo et 
al. 1998; Guina et al. 2000) and in other bacteria including Escherichia coli (Trent et al. 
2001; Yan et al. 2007; Herrera et al. 2010), Pseudomonas aeruginosa (Dorrer et al. 
1977; Ernst et al. 1999), Proteus mirabilis (McCoy et al. 2001; Wang et al. 2008), 
Bordetella bronchiseptica (Banemann et al. 1998; West et al. 2000). In Salmonella, two-
component regulatory systems including PhoP/PhoQ and PmrA/PmrB contributed 
significantly to LPS modifications and AMP resistance by modulating the  transcription 
of genes involved in the modification of lipid A, the bioactive component of LPS (Gunn 
et al. 1996; Gunn et al. 1998). In response to low extracellular Mg2+ or Ca2+, PhoP/PhoQ 
directly activated pagP and ugtL genes for LPS modification (Guina et al. 2000). PagP is 
an outer membrane protein essential for addition of palmitate to Salmonella lipid A, 
leading to the enhanced resistance of S. typhimurium to α-helical AMPs (Guina et al. 
2000). UgtL is an inner membrane protein that promotes the formation of 
monophosphorylated lipid A in the LPS and contributes resistance to polymyxin B (PM) 
and α-helical AMP magainin (Shi et al. 2004). By mediating activation of the second 
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two-component system PmrA/PmrB under low  Mg2+ conditions, PhoP/PhoQ also 
indirectly activated genes required for modification of lipid A with aminoarabinose 
(Gunn et al. 1998; Guina et al. 2000) and phosphoethanolamine (Gunn 2001). 
Specifically, the pbgP operon and ugd genes were essential for both the biosynthesis and 
incorporation of aminoarabinose into lipid A and are required for PM resistance (Lee et 
al. 2004). The pmrC gene encoding a putative aminotransferase mediated 
phosphoethanolamine modification of lipid A and confers PM resistance in S. 
typhimurium (Lee et al. 2004). 
In addition to LPS modification, Gram-negative bacteria also have other inducible 
mechanisms to resist AMPs via two-component or other regulatory systems. Direct 
degradation of AMPs by proteases is important for α-helical AMP resistance in some 
bacteria.  Salmonella outer membrane endopeptidase PgtE inactivated a panel of α-helical 
but not β-sheet AMPs and inactivation of PgtE resulted in increase in vitro sensitivity of 
Salmonella to many α-helical AMPs (Guina et al. 2000). PgtE homologies were found in 
outer membrane of E. coli (OmpT), and Yersnia (Pla) (Sugimura et al. 1988; Sodeinde et 
al. 1992), suggesting that this is a common AMP resistance mechanism in bacteria. 
Expression of E. coli OmpT increased survival of E. coli growth in the presence of 
protamine. OmpT degraded protamine at the extracellular facet of the outer membrane 
(Yeaman et al. 2003). Strains with deletion of this gene became hyper susceptible to 
protamine. Some Gram-negative bacteria can also secrete peptidase to inactivate AMPs. 
Secreted metallopeptidases ZmpA and AmpB were found in Burkholderia cenocepacia. 
These enzymes were shown to cleave human cathelicidin LL-37 and β-defensin-1, 
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respectively (Kooi et al. 2009). In addition to AMP enzymatic degradation, there also 
have been  numbers of studies on the role of efflux pumps in inducible AMP resistance. 
In Neisseria gonorroeae, efflux pump MtrCDE expression was increased in the presence 
of protegrin-1 and human cathelicidin LL -37 (Shafer et al. 1998). Similarly, the efflux 
pump RosA/RosB in Yersinia was found to be induced in the presence of AMPs such as 
polymyxin B (Bengoechea et al. 2000). Collectively, resistance to AMPs in bacteria is 
mediated by membrane potential, modification of bacterial membrane, production of 

















Table 1. Nomenclature of chicken β-defensins 
No. New gene/protein 
name 
RefSeq definition Lynn/Higgs et al. 
definition 
Xiao et al. 
definition 




Gallinacin 1 (GAL1) Gallinacin 1 
(GAL1) 




Gallinacin 2 (GAL2) Gallinacin 2 
(GAL2) 





Gallinacin 3 (GAL3) Gallinacin 3 
(GAL3) 
4 Avian beta-defensin 
4 (AvBD4) 





5 Avian beta-defensin 
5 (AvBD5) 





6 Avian beta-defensin 
6 (AvBD6) 





7 Avian beta-defensin 
7 (AvBD7) 





8 Avian beta-defensin 
8 (AvBD8) 





9 Avian beta-defensin 
9 (AvBD9) 





10 Avian beta-defensin 
10 (AvBD10) 























































Antimicrobial peptides (AMPs) function as critical innate barriers limiting 
bacterial infections at the gastrointestinal mucosal surface. Recently, AMPs also became 
recognized as a novel class of antibiotics to control pathogens. As an important strategy 
to evade killing by host innate immunity and by novel peptide antibiotics, the 
mechanisms of AMP resistance in C. jejuni are critical to understand, but are still 
unknown. In this study, Polymyxin B (PM), a peptide antibiotic, was used as a model 
peptide to study mechanisms of AMP resistance in Campylobacter. Using bioinformatic 
and microarrays in conjunction with molecular approaches, we observed that several 
lipooligosaccharide (LOS) synthesis genes (galU, waaC, waaF, neuB, and cgtA) were 
involved in PM resistance in Campylobacter. Inactivation of GalU also resulted in 
significantly reduced colonization ability of C. jejuni in chickens. Examination of the 
sequences encoding various two-component regulatory systems in two PM resistant 
mutants did not identify any mutations, which is different from what has been observed 
in other Gram-negative bacteria. Transcriptome analysis of PM resistant mutant using 
microarray showed that Cj0811, which is likely involved in lipid A synthesis, contributed 
to PM resistance. However, the identified genes were not involved in resistance of 
Campylobacter to physiologically relevant AMPs such as chicken host AMPs and anti-
Campylobacter bacteriocins (BCNs). Therefore, PM may not be an ideal surrogate to 
study Campylobacter resistance to physiologically relevant AMPs. Natural AMPs should 





Campylobacter has emerged as the leading bacterial cause of human 
gastroenteritis in the United States and other industrialized countries (Ruiz-Palacios 
2007). This pathogenic organism is also associated with Guillain-Bare syndrome, an 
acute flaccid paralysis that may lead to respiratory muscle compromise and death. In the 
United States, the estimated cases of campylobacteriosis are more than 2 million. Total  
economical and medical costs were estimated 1.5 to 8 billion US dollars each year 
(Buzby et al. 1997). Poultry and their products are the major sources for human 
Campylobacter infections (Kassenborg et al. 2004). In parallel to its increased 
prevalence, Campylobacter has become increasingly resistant to clinical antibiotics, 
posing a serious threat to public health (Allos 2001).  Therefore, development of effective 
intervention strategies is urgently needed to prevent and control Campylobacter 
infections in humans and animal reservoirs.  
Antimicrobial peptides (AMPs) are a major component of  host defense and 
function as critical innate barriers limiting microbial infections at the gastrointestinal 
mucosal surface in animals (Yeaman et al. 2003; De Smet et al. 2005; Brown et al. 2006). 
Recently, AMPs also became recognized as a novel class of antibiotics (peptide 
antibiotics) and have been proposed as future anti-infective products to control zoonotic 
pathogens in the avian intestinal tract. Notably, some chicken commensal bacteria-
produced AMPs, also called “bacteriocins” (BCNs), dramatically reduced C. jejuni 
colonization in chickens and turkeys and are being directed toward on-farm control of 
this pathogen (Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006).  As an important 
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strategy to evade killing by avian innate immunity and by novel peptide antibiotics, the 
mechanisms of AMP resistance are still unknown in C. jejuni. Availability of this 
information is not only critical to reveal novel virulence determinants contributing to in 
vivo survival of C. jejuni but also is important to better depict the modes of AMP action 
and facilitate the development of potent peptide antibiotics to reduce C. jejuni load in 
poultry. The recent completion of several C. jejuni whole genome sequences allows us to 
comprehensively identify genetic loci required for AMP resistance using functional 
genomic approaches. 
Polymyxin B (PM), an AMP produced by bacterium Paenibacillus polymyxa, has 
been widely and successfully used for studying AMP resistance in bacteria including 
different enteric pathogens (Ernst et al. 2001; Finlay et al. 2004). Although PM bears 
little structural resemblance to the host defense AMPs, inactivation of the genes 
responsible for PM resistance usually resulted in increased susceptibility of bacteria to a 
variety of innate AMPs, leading to reduce virulence of the mutants in animal model 
system (Ernst et al. 2001). Therefore, studying mechanisms of PM resistance in 
Campylobacter may reveal novel virulent determinants required for in vivo adaptation of 
Campylobacter. Furthermore, PM is easily available compared to most natural AMPs and 
is ideal for large-scale functional genomics studies. Thus, investigation of PM resistance 
likely reveals genes important for Campylobacter resistance to physiologically relevant 
AMPs. 
In our recent study, using random transposon mutagenesis, we identified several 
genetic loci contributing to PM resistance including GalU, an enzyme involved in LOS 
 
 34 
synthesis (Lin et al. 2009). In this study, we continue to evaluate the role of galU in AMP 
resistance and in vivo colonization of Campylobacter in chickens. The contribution of 
other LOS synthesis genes (waaC, waaF, neuB, and cgtA) to AMP resistance was also 
determined. In addition, several molecular approaches including microarray and sequence 
comparison were used to further determine the mechanisms of Campylobacter resistance 
to PM and other AMPs. 
MATERIALS AND METHODS 
Major bacterial strains and growth conditions. Bacterial strains and plasmids 
used in this study are listed in Table 2. Campylobacter strains were routinely grown in 
Mueller-Hinton (MH) broth (Difco) or on MH agar at 420C under microaerobic 
conditions, which was generated by CampyGen Plus (Oxoid) gas pack in an enclosed jar. 
When needed antibiotics kanamycin (Kan) or chloramphenicol (Cm) were added into 
MH broth or agar to desired concentrations. E. coli strains were grown at 370C in Luria-
Bertani (LB) medium with shaking and supplemented with 30 μg/ml of Kan or 20 μg/ml 
of Cm. 
in vitro selection of PMr mutants. The PMr mutants were obtained by single or 
stepwise in vitro selection methods. Briefly, to obtain the PMr mutant JL216 (MIC = 64 
µg/ml), an overnight culture of C. jejuni 81-176 grown on MH agar plates was harvested 
and approximately 1012 cells were spread on MH agar plate containing 128 µg/ml of PM. 
The plates were incubated for two days under microaerophilic conditions at 420C. The 
resistant mutants were collected and confirmed by MIC test with PM. The spontaneous 
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PMr mutant JL148 (MIC = 64 µg/ml) was obtained from stepwise selection. Briefly, 
approximately 1012 CFU of C. jejuni 81-176 were spread on MH agar containing 32 
µg/ml of PM. The resistant mutants selected after 2 days of incubation were subsequently 
used for additional rounds of selection on plates containing increasing concentrations of 
PM. One PMr mutant named JL148 (MIC = 64 µg/ml) was obtained from the third step of 
selection using plates with 128 µg/ml of PM. 
PCR, qRT-PCR and sequence comparison. Key primers used in this study for 
PCR and sequencing are listed in Table 3. PCR was performed in a 50 μl mixture 
containing each deoxynucleosite triphosphate at a concentration of 200 nM, each primer 
at a concentration of 200 nM, 2.0 nM MgCl2, 50 ng of C. jejuni genomic DNA, and 2.5 U 
of Platinum Taq DNA polymerase (Invitrogen). PCR products were purified by 
QIAquick PCR Purification Kit (Qiagen), when needed, for cloning or sequencing 
analysis. Real-time quantitative PCR was performed as described previously (Guo et al. 
2008) using gene specific primers (data not shown). Primers for real time qRT-PCR were 
designed using Primer3 online interface (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). Each primer was subsequently analyzed with MFold 
(http://www.bioinfo.rpi.edu/applications/mfold/old/rna/) to avoid secondary RNA 
structures and hairpin loops. 16S RNA primers were set for internal control. The qRT-
PCR was performed as described previously (Lin et al. 2005). The relative expression of 
different genes in wild type and PM resistant mutant was normalized with 16S RNA gene 
amplified from the corresponding sample. Differential expression was determined by 
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threshold cycle (CT) method (Guo et al. 2008) and two independent experiments with 
triplicates conducted for each independent experiment for each sample.  
Antibiotic susceptibility test. The susceptibilities of C. jejuni strains to PM and 
other antimicrobials were determined by standard microtiter broth dilution method with 
an inoculum of 106 bacterial cells/ml as described previously (Lin et al. 2002). Minimum 
inhibitory concentrations (MICs) were determined by the lowest concentration of a 
specific antimicrobial showing complete inhibition of bacterial growth after two days of 
incubation at 420C. The tested AMPs were purchased from Sigma (St. Louis, MO; PM, 
magainin, cecropin A) or kindly provided by Dr. Norman Stern (USDA; bacteriocin OR-
7 and E-760). 
DNA isolation and natural transformation. Chromosomal DNA was isolated 
from Campylobacter using the Wizard Genomic Purification Kit (Promega) according to 
the manufacturer’s instructions. Biphasic natural transformation method was performed 
as described previously (Davis et al. 2008). Briefly, C. jejuni cultures grown overnight on 
MH agar plates were collected and re-suspended in MH broth to OD600 of 0.5. Bacterial 
suspensions (0.5ml) were transferred to sterilized tubes and incubated at 42oC under 
microaerophilic conditions for three hours. One μg DNA of donor strain which carries the 
chloramphenicol resistant gene (cm) or kanamyxin resistance gene (kan) marker was 
added to culture. After five hour incubation, bacterial cultures were spread on MH agar 
containing Cm or Kan to select transformants. The transformants were confirmed by PCR 
using specific primers. 
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            Whole genome microarray analysis. We used microarrays to compare the 
transcriptome of wild-type C. jejuni 81-176 with that of PM resistant mutant JL216 
(Table 2). The microarray glass slides (C. jejuni OciChipTM) were purchased from 
Ocimum Biosolutions (Indiana). The bacterial RNA isolation, cDNA synthesis and 
labeling, microarray hybridization, and data collection and analysis were detailed in 
previous publication (Guo et al. 2008). Briefly, RNAprotectTM Bacteria Reagent (Qiagen) 
was immediately added to mid-log phase C. jejuni culture (OD of approximately 0.12) to 
keep the bacterial transcriptome intact. Total RNA was then extracted and purified using 
RNeasy Mini Kit (Qiagen). Twelve μg of total RNA was reverse transcribed and 
fluorescently labeled with Cy3 or Cy5 (Amersham) using SuperScript Indirect cDNA 
labeling System (Invitrogen). Equal volumes of Cy3 and Cy5-labeled cDNA were mixed, 
dried under vacuum and then suspended in 120 μl of hybridization buffer (Ocimum 
Biosolutions). A second microarray slide was hybridized with dye swap to generate 
technical replicates. The experiment was replicated five times using RNA from five 
independent experiments. Hybridization slides were scanned at 650 nm for Cy5 and 550 
nm for Cy3 using Axon GenePix 4000 Scanner at 10-μm resolution. The fluorescent 
signal intensities were collected using GenePix Pro4 software and the data was 
normalized with removal of outliers and loess smoothing of ratio-intensities plots for 
each array. The data was then analyzed using mixed linear models for each gene, 
accounting for array variation, dye swap bias, treatment effects. P-value was adjusted by 
a False Discovery Rate of 5%. R-package (version 0.5.12 2003) was used for data 
normalization and statistical analysis. For this study, we chose a P value of < 0.05 and a 
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change  ≥  2.0-fold as the cutoff for significant differential expression between C. jejuni 
81-176 and PM resistant mutant JL216. 
         Construction of isogenic Cj1506c and Cj0811 mutants. A 1.3-kb fragment was 
amplified from JL28 genomic DNA using primers Cj1506c-R and Cj1506c-F (Table 3). 
The PCR product was purified and ligated into TOPO TA cloning® vector, resulting in 
pCj1506c. A 0.8-kb fragment of chloramphenicol resistant cassette (cm) with an XbaI 
restriction site was amplified from plasmid pUOA18 (Wang et al. 1990) using primers 
CmXbaI-R and CmXbaI-F (Table 3). The PCR product, which was digested with XbaI 
was ligated into pCj1506c, which was also digested with XbaI prior to ligation. The 
ligation mix was transformed into E. coli DH5α, and one transformant bearing construct 
pcmCj1506c was selected on LB agar containing 20 μg/ml of Cm. The construct 
pcmCj1506c containing chloramphenicol resistant cassette was introduced into JL28 by 
biphasic natural transformation method. One transformant was selected on MH plus 6 
μg/ml of Cm and confirmed by PCR. 
           The same strategy was used to generate a Cj0811 isogenic mutant of C. jejuni 
JL216. Briefly, an approximately 1.2-kb fragment of Cj0811 along with 200-bp of its 
upstream and downstream regions was amplified using genomic DNA of JL216 and 
primers Cj0811-F and Cj0811-R (Table 3). The PCR product was purified and ligated 
into a TOPO TA cloning® vector (Invitrogen) resulting in plasmid pCj0811. The 
chloramphenicol resistant cassette (cm) with introduced PflmI restriction sites at two ends 
was amplified from pUOA18 (Wang et al. 1990). The PflmI digested cm cassette was 
inserted into pCj0811 which was digested by PflmI prior to ligation. One mutant 
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construct designated as pcmCj0811 was obtained and used for natural transformation 
using JL216 as the recipient strain. One transformant (JL417) bearing cm inserted in 
Cj0811 was selected on MH agar plate containing 6 μg/ml of Cm and confirmed by PCR 
using primers Cj0811-F and Cj0811-R. 
          Chicken experiment. One day old chickens (a kind gift from Hubbard Hatchery, 
Pikeville, TN) were randomly assigned into four groups (5 chickens per group). All birds 
were placed in sanitized wire cages with unlimited access to feed and water. All 
antibiotic-free feed was prepared by the feed mill at the Johnson Animal Research and 
Teaching Unit, University of TN. Prior to inoculation with C. jejuni strains, all birds were 
confirmed to be free of Campylobacter by culture of cloacal swabs and plated on MH 
agar containing selective supplements that inhibit majority of intestinal microflora. At 
day four of age, chickens in each  group were inoculated with one of following 4 
individual Campylobacter strains via oral gavage with inoculums of 107 CFU per chick: 
wild type C. jejuni 81-176, PMr mutant JL280,  isogenic galU mutants JL281 or  JL282 
(Table 2). Fecal samples were collected at 7 and 11 days post inoculation (DPI) and 
plated on MH agar containing selective supplements. Campylobacter colonies were 
enumerated after two days of incubation under microaerophilic conditions at 420C. The 
detection limit of plating method was approximately 100 CFU/gram feces. The 
significant difference in Campylobacter colonization levels (log10 transformed CFU/g of 
feces) at each sampling point between groups was calculated using Student’s t test. A P-





The gene galU is responsible for PM and other AMP resistance in C. jejuni. 
In our previous study, galU was observed to be responsible for PM resistance in PMr 
mutant JL148. In this study, we further tested sensitivity of galU mutant to AMPs from 
various sources. As shown in Table 4, inactivation of the galU also led to increased 
sensitivity to other AMPs such as colistin, magainin, cecropin-A, and bacitracin. 
Complementation of galU (JL230) fully restored resistance levels back to its parent strain 
JL148. Although galU was found contributing to several AMPs, it was not responsible 
for resistance to chicken AMPs such as fowlicidin-1 and -2, and bacteriocins OR-7 and 
E-760.  
LOS required for PM resistance in Campylobacter. We further examined if 
other LOS synthesis genes are involved in PM resistance, including neuB, ctgA, waaC, 
and waaF. As shown in Table 5, inactivation of these genes in PM resistant strain JL216 
resulted in increased susceptibility to PM (8 to 32-fold reductions in MIC).  
GalU is essential for colonization of Campylobacter in chickens.  Because 
mutation in galU resulted in significant truncation of LOS of C. jejuni and led to 
increased susceptibility to various AMPs (Lin, 2009), GalU may play an important role in 
the in vivo colonization of C. jejuni by mediating AMP resistance. To test this hypothesis, 
strains wild type C. jejuni JL242, derivative spontaneous PMr mutant JL280 and their 
corresponding isogenic galU mutants were inoculated into four chicken groups.  As 
shown in Fig 1, wild-type C. jejuni JL242 colonized in 80% of the chickens at day 7 post 
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inoculation, and by day 11 post inoculation, all of the chickens were colonized by JL242 
with a shedding level of about 105 CFU/gram feces. In contrast, C. jejuni was not 
detected throughout the study in any of cloacal swabs collected from the chickens 
inoculated with JL280 or galU mutants JL281 and JL282. 
Sequence comparison of signal transduction systems between wild type and 
PM resistant mutants. Many studies have demonstrated that Gram-negative bacteria can 
govern inducible antimicrobial peptide (AMP) resistance via surface modifications that 
are controlled by two-component regulatory systems (Groisman et al. 1997; Ernst et al. 
2001; Groisman 2001; Cheng et al. 2010; Fernandez et al. 2010). Point mutations 
occurring in such two-component systems (e.g. PhoP/PhoQ, PmrA/PmrB) could result in 
acquired resistance to PM and other AMPs. We hypothesized that the mutants (JL216 and 
JL148) with acquired PM resistance may have mutations in two-component regulatory 
systems; identification of such two-component system(s) is critical to study the 
regulatory mechanisms of AMP resistance in Campylobacter.  According to the C. jejuni 
NCTC 11168 genome sequence (Parkhill et al. 2000), twelve putative two-component 
regulators and seven two component sensors (histidine kinase) exist. In this study, nine 
regulators, five histidine kinases, and six signal transduction systems (Table 6) were PCR 
amplified from wild-type 81-176 and its two PM resistant mutants JL148 and JL216 
using specific primers (Table 3). The PCR fragments were sequenced and compared 
using DNAStar. No sequence difference was found in these regulatory genes between 
wild-type 81-176 and its PM resistant derivatives. 
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Transcriptional profiling of PM resistant mutant JL216. A microarray 
experiment was performed to compare the transcriptome of PM resistant mutant JL216 
with that of its parent strain C. jejuni 81-176. The microarray result in conjunction with 
qRT-PCR revealed that the gene (Cj0811) encoding putative tetraacyldisaccharide 4`-
kinase LpxK, which is likely involved in  lipid A synthesis, was up-regulated (2 fold) and 
two other genes down-regulated Cj0403c (4-fold) and Cj1506c (16-fold) (Table 7). The 
Cj1506c and Cj0811 isogenic mutants were constructed by site-targeted mutagenesis. 
Only isogenic Cj0811 mutant showed increased sensitivity to PM (2-fold) and 
inactivation of Cj1506c did not affect MIC of PM compared with its parent strain (data 
not shown). 
DISCUSSION 
Modifications of LPS in conferring resistance to PM and other AMPs have been 
found in many Gram-negative bacteria such as Salmonella, Klebsiella, Proteus miralitis, 
and E. coli (Guo et al. 1998; Gunn et al. 2000; Campos et al. 2004; Moon et al. 2009; 
Cheng et al. 2010). Unlike other Gram-negative bacteria, Campylobacter only has LOS 
(not LPS) and capsule polysaccharide (CPS) on the surface (Karlyshev et al. 2005). The 
LOS comprises two main components: the hydrophobic lipid A anchor and an 
oligosaccharide consisting of a conserved inner core and a hyper variable outer core 
(Golec 2007). LOS plays multiple roles in pathogenesis of Campylobacter including 
acting as endotoxin, adherence factor, and a factor that maintains stability of the outer 
membrane and protects the cells from environmental stress (Kanipes et al. 2008; Jeon et 
al. 2009). The enzymes responsible for LOS production in Campylobacter include GalU, 
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WaaC, WaaF, WaaM, WaaV (inner core), LgtF, AgtA, and GalT (outer core) (Kanipes et 
al. 2008; Naito et al. 2010). In our study, we demonstrated that LOS production in C. 
jejuni is required for PM resistance.  
Lipid A core modifications including addition or alteration of fatty acid chains, or 
addition of polar groups such as phosphoethanolamine, 4-amino-4-deoxy-L-arabinose, 
and/or palmitate can confer resistance to AMPs including PM in many Gram-negative 
bacteria (Wang et al. 2010). In our study, inactivation of the gene Cj0811 which encodes 
putative tetraacyldisaccharide 4`-kinase (LpxK) responsible for addition of fatty acid 
chains to a disaccharide backbone resulted in slightly increased susceptibility to PM and 
magainin. However, there were no MIC difference caused by Cj0811 with respect to 
chicken cathelicidins (F-1 and F-2), or bacteriocins (OR-7 and E-760) (data not shown). 
Recently, it has been reported that addition of a polar group phosphoethanolamine at the 
1 or 4-position in the disaccharide backbone of lipid A resulted in increased resistance of 
C. jejuni to PM (Cullen et al. 2010). Wosten et al (2010) reported that alteration of the 
disaccharide backbone in Campylobacter lead to mildly increased sensitivity to PM and 
other AMPs including chicken cathelicidin-1 and colistin (van Mourik et al. 2010).  
The gene galU is critical for production of uridine diphosphate (UDP)-glucose, a 
sugar precursor  required for polysaccharide formation and LOS outer core synthesis in 
Campylobacter and other Gram-negative bacteria (Weickert et al. 1993). This study 
demonstrated that defects in the outer core of LOS due to GalU mutation significantly in 
vivo colonization of Campylobacter in chickens. It is not surprising that the in vitro-
selected  PM resistant mutant JL280 also reduced colonization levels in chickens because 
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the mutation(s) which occurred in JL280 may exert pleiotropic effects on the phenotype 
of C. jejuni in addition to PM resistance, consequently leading to an overall negative 
impact on the colonization ability of the mutant. Similar findings also were observed in 
that both an AMP-sensitive PhoP-null mutant and an AMP-resistant mutant with a 
mutation in the two-component regulatory system PhoP/PhoQ were avirulent in a mouse 
model and displayed pleiotropic mutant phenotypes (Gunn et al. 1996; Groisman 2001). 
Our result was also consistent with the recent report that inactivation of genes 
contributing to synthesis of either inner core (WaaF) or outer core (LgtF) of LOS 
abolished Campylobacter in vivo colonization using a chicken model system (Naito et al. 
2010). 
Mutations occurring in two-component regulatory systems could result in 
acquired resistance to PM as well as AMPs in other bacteria (Roland et al. 1993; Gunn et 
al. 1996; Guo et al. 1998). Sequence analysis of multiple two-component regulatory 
systems in PM resistant mutants did not reveal any mutations when compared to its wild-
type PM-sensitive parent strain, suggesting that Campylobacter may use different 
mechanisms to acquire AMP resistance. These sequence analyses were also consistent 
with the microarray data comparing the transcriptome of wild type C. jejuni 81-176 and 
its derivative PMr mutant JL216. If the mutation occurred in the two-component 
regulatory systems, many genes would have been found differentially expressed. In fact, 
very small numbers of genes (three genes) were found differently expressed between wild 
type and PM resistant mutant from microarray data analysis. Comparative genomics 
revealed small differences between C. jejuni 11168 and 81-176 (Pearson et al. 2003), and 
 
 45 
because of the unavailability of microarray glass slides designed specifically for  C. jejuni 
81-176, we could not rule out the possibility that using C. jejuni 11168-based microarray 
glass slides for hybridization of C. jejuni 81-176 may fail to identify the genes that are 
not present in C. jejuni 11168. 
 Despite discovery of genes involved in PM resistance in this study, these genes 
are not required for Campylobacter resistance to physiologically relevant AMPs (e.g. 
chicken host AMP fowlicidins) and to the anti-Campylobacter BCNs. It is likely that 
resistance to PM in Campylobacter is unique, possibly mediated by mutations in the 
specific targets of PM. The results from this study suggested that PM is not an ideal 
surrogate for studying Campylobacter resistance to physiologically relevant AMPs such 
as bacteriocins and fowlicidins. More studies are needed to reveal both common and 
unique mechanisms of Campylobacter resistance to natural AMPs such as bacteriocins 



















Table 2. Major bacterial strains and plasmids used in this study (Chapter II) 
 
Strains or 
plasmids Description Sources or references 
Strains 
  
JL28 81-176 human isolate with low motility  (Black et al. 1988) 
JL148 81-176 derivative PM resistant mutant obtained 
by stepwise selection in vitro, MIC = 64 μg/ml 
(Lin et al. 2009) 
46B1 JL148 derivative,  galU::kan (Lin et al. 2009) 
JL230 46B1 /pGalU (Lin et al. 2009) 
JL216 81-176 derivative, PM resistant mutant obtained 
by single step selection in vitro, MIC = 64 μg/ml 
This study 
JL320 81-176 derivative, waaC::cm (Kanipes et al. 2006) 
JL321 81-176 derivative, waaF::cm (Kanipes et al. 2004) 
JL322 81-176 derivative, ctgA::cm (Guerry et al. 2002) 
JL323 81-176 derivative, neuB::cm (Guerry et al. 2002) 
JL328 JL216 derivative, neuB::cm This study 
JL329 JL216 derivative, cgtA::cm This study 
JL330 JL216 derivative, waaC::cm This study 
JL331 JL216 derivative, waaF::cm This study 
JL317 JL216 derivative, galU::kan This study 
JL388 81-176 derivative, Cj1506c::cm This study 
JL242 81-176 human isolate, highly motile (Black et al. 1988) 
JL281 JL242 derivative, galU::kan This study 
JL280 JL242 derivative spontaneous PMr mutant This study 
JL282 JL280 derivative,  galU::kan (Lin et al. 2009) 
JL417 JL216 derivative,  Cj0811::cm This study 
Plasmids   
pGEM-T 
 
PCR cloning vector, Ampr Promega 
pCj1506c pGEM-T Easy containing 1.3-kb gene fragment 
Cj1506c of JL28 
This study 
pcmCj1506c pCj1506c with cm cassette inserted in Cj1506c This study 
pCj0811 pGEM-T Easy containing 1.2-kb gene fragment 
Cj0811 of JL216 
This study 
pcmCj0811 pCj0811 with cm cassette inserted in Cj0811 This study 
E.coli    
DH5α F– 80lacZ M15 (lacZYA-argF)U169 recA1 
endA1 hsdR17 (rk–, mk+) phoA supE44 thi-1 





Table 3. Key primers used in this study (Chapter II) 
Primers Sequence (3’-5’)a Target genes 
Cj1222c-R TGCCAGATATGAGAGGTATG Cj1222c 
Cj1222c-F AAGAGGCAGGGGATATTGCT  
Cj1223c-R TTTTGATACCATAATGCAAAAA Cj1223c 
Cj1223c-F TTGATAAGAATTTTGATACAATGAT  
Cj1226c-R AAAACAAATTTACCCCATCTTCA Cj1226c (CprR) 
Cj1226c-F GGGTGGAGTGGTAAGTCGTG  
Cj1227c-R CACTAACCCCAGCAAAAATAAAA Cj1227c (CprS) 
Cj1227c-F TGCGACTTTGCTTGTGCTTA  




Cj1262-R GTGCGAGTTTCATACCATCG Cj1262c (RacS) 
Cj1262-F CATCGGTCGCTTAAGGGTAA  
Cj0246c-R AAAACCTTTCCGGTTGAAGC Cj0246c 
Cj0246c-F TTTGCAAAAATTGCAGAGG  
Cj1189c-R CAAGATGAGAGAGCTCAAGGTG Cj1189c 
Cj1189c-F AAGCCTTGTTGCTGTTCTGC  
Cj1191c-R TTTTGTAATTCAGTTTGCTTTTTG Cj1191c 
Cj1191c-F TGACACCTAAAACACCGATAACA  
Cj1492c-R TGGCGTTATTGTTTGTTACGG Cj1492c 
Cj1492c-F CCCTCATCTCCATTTTGAGC  
Cj0951c-R GTACTAGCACAACCCGCAAA Cj0951c 
Cj0951c-F GTACTAGCACAACCCGCAAA  
Cj1491c-R TGTTTTATATTTTAAGGCTAAATCAGT Cj1491c 
Cj1491c-F ATGGAAAAGACGGGGCTTG  
Cj0889c-R CCCTCGTTTGCGCTAAAAT Cj0889c 
Cj0889c-F AAGTGTTAGGGGTATTGGCTCTAAA  
Cj0890c-R AACCCAAAAATCAAAGCCAAT Cj0890c 
Cj0890c-F GAGGCGTGTGTATTTGTCCA  
Cj0643-R GCAATGCGTATCAACAATCC Cj0643 (CbrR) 
Cj0643-F AAAAATTTCCTTTCTTTTGAAAAC  
Cj1608-R GCAAGTGCCTAGCAAACCTT Cj1608 
Cj1608-F AAGCCACAACAACGGAAAAA  




Cj1262-R TGAAAAGGTGATAAAGCAAGC Cj1262 
Cj1262-F CATCGGTCGATTAAAGGTAA  
Cj0793-R CGTTTTGGGGTGAAAAGAAA Cj0793 
Cj0793-F TGTGAACAGAATTTGCTTTTACTTG  
Cj0448c-R GCTTCATGTAAAAGATGAACTTAGC Cj0448c 
Cj0448c-F GCCTTTGCTTGATTTTGCTT  
Cj1506c-R GGCTGAGGACAAGATAGATTGC Cj1506c  
Cj1506c-F GCAAAAAGACATAGAAGA  




Cj0811-R GCGAATTGCTTTTAGGTTATGG LpxK 








abold and underlined sequences are enzyme restriction sites 
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Table 4. Susceptibilities of C. jejuni JL148, isogenic galU mutant 46B, and 





JL148 46B1 JL230 
Polymyxin B 64 4 64 
Colistin 64 2 64 
Magainin 32 16 32 
Cecropin A 4 2 4 
Bacitracin 1,024 512 1,024 
Fowlicidin-1 4 4 NDa 
Fowlicidin-2 8 8 ND 
OR-7 1 1 ND 
E-760 1 1 ND 
 
aND: Not determined 
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Table 5. LOS required for PM resistance in Campylobacter 
Strains Isogenic mutants Function of inactivated genes MIC 
(µg/ml) 
    
JL216 N/A N/A 64 
JL328 JL216 derivative, neuB::cm N-acetylneuraminic acid synthetase 
 
2 
JL329 JL216 derivative, cgtA::cm Beta-1,4-N-cetylgalactosaminyltransferase 
 
8 
JL330 JL216 derivative, waaC::cm Lipopolysaccharide heptosyltransferase I 
 
8 
JL331 JL216 derivative, waaF::cm ADP-heptose--LPS heptosyltransferase II 
 
8 




N/A, Not applicable 
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Table 6. Putative two-component regulatory and signal transduction systems of C. jejuni 
11168 used for sequence comparison 
 
Gene name Putative functions 
Cj1222c Two-component sensor histidine kinase (DccS) 
Cj1223c Two-component regulator (DccR) 
Cj1226c Putative two-component sensor histidine kinase (CprR) 
Cj1227c Putative two-component regulator (CprR) 
Cj1262 Two-component sensor histidine kinase (RacS) 
Cj1261 Two-component regulator (RacR) 
Cj1492c Two-component sensor histidine kinase 
Cj1491c Putative two-component regulator 
Cj0889c Putative sensory transduction histidine kinase 
Cj0643 Two-component regulator (CbrR) 
Cj1608 Putative two-component regulator 
Cj0355c Putative two-component regulator 
Cj1191c PAS domain containing signal-transduction sensor protein 
Cj0448c Putative MCP-type signal transduction protein 
Cj1506c Putative MCP-type signal transduction protein 
Cj0246c Putative MCP-domain signal transduction protein 
Cj1189c Bipartate energy taxis response protein CetB 
Cj0951c Putative MCP-domain signal transduction protein 













     
Cj0811 LpxK; putative tetraacyldisaccharide 4`-kinase 1.84 2.1 0.02 
Cj0403c Hypothetical protein - 2.0 - 4 5.10E-06 





Figure 1. GalU is required for chicken colonization. Colonization of C. jejuni JL242, its 
derivative PMr mutant JL280, and their isogenic galU mutants JL281 and JL282 
respectively in chickens. The shedding levels of Campylobacter in chicken colonized by 
C. jejuni at 7 and 11 days postinoculation (DPI). Each data point represents the mean 











PREVALENCE, DEVELOPMENT, AND MOLECULAR MECHANISMS OF 




Bacteriocins (BCNs) are antimicrobial peptides produced by bacteria with narrow 
or broad spectrum of antimicrobial activity.  Recently, several unique anti-
Campylobacter BCNs have been identified in commensal bacteria isolated from chicken 
intestine. These BCNs dramatically reduced C. jejuni colonization in poultry and are 
being directed toward on-farm control of Campylobacter.  However, no information 
exists concerning prevalence, development, and mechanisms of BCN resistance in 
Campylobacter.  In this study, susceptibilities of 137 C. jejuni and 20 C. coli isolates to 
the anti-Campylobacter BCNs OR-7 and E-760 were examined. Only one C. coli strain 
displayed resistance to the BCNs (MIC = 64 μg/ml) while others were susceptible with 
MIC ranging from 0.25 to 4 μg/ml. BCN resistant (BCNr) C. coli mutants also were 
obtained by in vitro selection but all of them displayed low-level resistance to the BCNs 
(MIC = 8 to 16 μg/ml). The acquired BCN resistance in C. coli could be transferred at 
intra- and inter-species levels in Campylobacter by biphasic natural transformation. 
Genomic examination of the BCNr mutants using DNA microarray and random 
transposon mutagenesis revealed that the multidrug efflux pump CmeABC contributes to 
both intrinsic and acquired resistance to the BCNs. Together, this study represents the 
first report and a major step forward in understanding BCN resistance in Campylobacter, 
which will facilitate the development of effective BCN-based strategies to reduce 




Campylobacter species including C. jejuni and C. coli are the most common 
bacterial causes of human gastroenteritis in the United States (Ruiz-Palacios 2007). 
Human Campylobacter illnesses are caused primarily by C. jejuni (~90%) and 
secondarily by C. coli (~10%). This group of pathogenic organisms causes watery 
diarrhea and/or hemorrhagic colitis in humans and is associated with Guillain-Barre 
syndrome, an acute flaccid paralysis that may lead to respiratory muscle compromise and 
death (Nachamkin et al. 1998). There are more than two million estimated cases of 
human campylobacteriosis in the United States each year, and the annual medical and 
productivity costs resulting from Campylobacter infection are estimated at 1.5 to 8.0 
billion dollars (Buzby et al. 1997). Poultry, particularly chickens, are considered a major 
source of human campylobacteriosis (Kassenborg et al. 2004). Thus, on-farm control of 
Campylobacter in poultry would reduce risk of human exposure to this pathogen and 
have a significant impact on food safety and public health (Lin 2009). In particular, at the 
same time that prevalence of infection is increasing, Campylobacter has become 
increasingly resistant to antibiotics, including fluoroquinolones and macrolides, the major 
drugs of choice for treating human campylobacteriosis (Luo et al. 2005), which raises an 
urgent need for novel strategies to prevent and control Campylobacter colonization in 




To date, three general strategies have been proposed to control Campylobacter in 
poultry on the farm, including 1) reduction of environmental exposure (biosecurity 
measures); 2) an increase in poultry’s host resistance to reduce Campylobacter carriage in 
the gut (e.g. competitive exclusion, vaccination, and host genetic selection); and 3) the 
use of antimicrobial alternatives to reduce and even eliminate Campylobacter from 
colonized chickens (e.g. bacteriophage therapy (Lin 2009)). Effective implementation of 
biosecurity measures relies on a better understanding of risk factors and sources of 
Campylobacter for poultry (van Gerwe et al. 2009). Except for biosecurity measures, the 
other two general intervention approaches are currently not commercially available and 
are still under development. Notably, recent breakthroughs in the discovery and 
characterization of potent anti-Campylobacter bacteriocins (BCNs) may lead to an 
effective measure for on-farm control of Campylobacter in poultry (Lin 2009). BCNs are 
short antimicrobial peptides (AMPs) produced and exported by most bacterial species 
examined to date for the apparent purpose of destroying their competitors (Riley et al. 
2002). Many BCN-producing bacteria (e.g. lactic acid bacteria) are commensals in the 
intestine. Therefore, the intestinal BCN-producing bacteria may achieve competitive 
advantage and function as an innate barrier against pathogens in the host. The natural 
BCNs have been proposed as promising candidates for novel antimicrobials (Cotter et al. 
2005). Several anti-Campylobacter BCNs produced by chicken commensal bacteria, such 
as OR-7 from Lactobacillus salivarius (Stern et al. 2006), E-760 and E50-52 from 
Enterococcus faecium (Svetoch et al. 2008), and SRCAM from Paenibacillus polymyxa 
(Svetoch et al. 2005), have displayed potent killing effect in vitro. Oral administration of 
these BCNs dramatically reduced C. jejuni colonization in poultry intestine (5-8 log10 
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CFU/gram feces reductions). Thus, these natural anti-Campylobacter BCNs have been 
proposed as effective alternatives to therapeutic antibiotics and are being developed for 
on-farm control of Campylobacter (Lin 2009). 
 Although the above anti-Campylobacter BCNs have been demonstrated to be very 
effective in reducing C. jejuni colonization in poultry, several critical issues (e.g. 
production and resistance development) need to be addressed for future regulatory 
approval and public acceptability of this intervention measure. In this study, we examined 
prevalence, development, and molecular mechanisms of BCN resistance in 
Campylobacter using molecular and genomic approaches. Our findings strongly suggest 
that there is less resistance development for the anti-Campylobacter BCNs, such as OR-7 
and E-760 compared to traditional antibiotics. In addition, microarray and random 
transposon mutagenesis studies indicated that the multidrug efflux pump CmeABC 
contributes to both intrinsic and acquired resistance of Campylobacter to the BCNs. 
MATERIALS AND METHODS 
Bacteria strains, plasmids, and growth conditions. The major bacterial strains 
and plasmids used in this study are listed in Table 8.  Among the 157 strains used for the 
prevalence survey in this study, 137 isolates are C. jejuni while 20 isolates are C. coli. 
These Campylobacter strains were isolated from different hosts including human (15), 
bovine (5), chicken (111), turkey (1), pigs (4), as well as from the environment including 
mouse traps (5), bird droppings (5), and lagoons (1).  All of these strains were collected 
from 16 geographically diverse areas in the United States. These C. jejuni and C. coli 
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strains were routinely cultured in Mueller-Hinton (MH) broth (Difco) or on MH agar at 
420C under microaerophilic conditions, which was generated by CampyGen Plus (Oxoid) 
gas pack in an enclosed jar. When needed, MH media were supplemented with 
kanamycin (Kan), chloramphenicol (Cm), or BCNs at desired concentration. E. coli cells 
were grown at 370C in Luria-Bertani (LB) medium with shaking and supplemented with 
30 μg/ml of Kan or 20 μg/ml of Cm. 
Bacteriocins. The BCNs OR-7 and E-760 were purified from L. salivarius NRRL 
B-30514 and E. faecium NRRL B-30745, respectively, as described in recent publications 
(Stern et al. 2006; Line et al. 2008).  These BCNs were dissolved in sterile H2O and 
stored at -200C prior to use.  
BCN susceptibility test. The susceptibilities of C. jejuni and C. coli isolates to 
BCNs OR-7 and E-760 were determined by standard microtiter broth dilution method 
with an inoculum of 106 bacterial cells/ml as described previously (Lin et al. 2002). 
Minimum inhibitory concentrations (MICs) were determined by the lowest concentration 
of specific BCN showing complete inhibition of bacterial growth after two days of 
incubation at 42 0C. 
in vitro selection of BCNr C. jejuni and C. coli. BCN OR-7 was used as a 
selective agent for generating spontaneous BCNr mutants in vitro. Briefly, C. jejuni and 
C. coli strains were grown in BCN-free MH broth to late log phase. The cultures were 
centrifuged and the pellets were suspended in MH broth to a final concentration of 
approximately 1010 cells/ml. The cell suspensions were plated in duplicate on MH agar 
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plates containing 4, 8, or 16 μg/ml of OR-7. After two days of incubation, the BCNr 
colonies were enumerated and the frequency of emergence of BCN resistance was 
calculated, which is the ratio of CFU on BCN containing plates to CFU on BCN-free MH 
agar plates. The single-step in vitro-selected BCNr mutants were randomly selected and 
used for MIC test together with the corresponding parent strain. The experiment was 
repeated twice with triplicate measurements in in independent experiment. 
DNA isolation and natural transformation. Chromosomal DNA was isolated 
from Campylobacter using the Wizard Genomic Purification Kit (Promega) according to 
the manufacturer’s instructions. Natural transformation (biphasic method) was performed 
as described previously (Davis et al. 2008). The natural transformation efficiency was 
expressed as transformants per μg DNA per recipient CFU.  
Whole genome microarray analysis.  We used microarrays to compare the 
transcriptome of wild-type C. jejuni NCTC 11168 with its BCNr derivative JL341 (OR-7 
MIC = 8 μg/ml) (Table 8). The microarray glass slides (C. jejuni OciChipTM) were 
purchased from Ocimum Biosolutions (Indiana). The bacterial RNA isolation, cDNA 
synthesis and labeling, microarray hybridization, and data collection and analysis were 
detailed in our previous publication (Guo et al. 2008). The hybridization experiments 
were repeated five times (biological replicate, n = 5) by using total RNA isolated from 
five independent experiments. In this study, we chose a P value of < 0.05 and a change ≥ 
2.0-fold as the cutoff value for significant differential expression between C. jejuni 
NCTC11168 and its derivative BCNr mutant JL341. 
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           in vivo random transposon mutagenesis. The BCNr C. jejuni JL358, a 81-176 
derivative (Table 8), was subjected to in vivo transposon mutagenesis using EZ::Tn5™ 
<KAN-2> Transposome (Epicentre) as detailed in our previous publication (Lin 2009). 
Briefly, one microlitter of EZ::Tn5™<KAN-2> Transposome was used to electroporate 
C. jejuni JL358 competent cells. The Kanr transformants were individually picked and 
inoculated in 96-well microplates.  Following 2 days of incubation, cultures of mutants 
were replicated into microtiter plates containing 4 μg/ml of OR-7 (4-fold reduction of 
MIC of parent strain). Those mutants that could not grow in OR-7-containing medium 
were selected from initial plates and subjected to second screening to confirm increased 
sensitivities of the mutants to OR-7. To confirm specific genetic associated with the 
transposome insertion and the increased susceptibility of each mutant to BCN, 
backcrossing of the transposon mutations into the parent strain was performed using 
natural transformation (Davis et al. 2008). The MICs of BCN for the backcrossed 
mutants were determined together with parent strain C. jejuni JL358. Specific transposon 
insertion site of each mutant was determined by direct sequencing of the genomic DNA 
(Lin et al. 2009). Sequence analysis was performed using DNAStar software package. 
        PCR and Real-time qRT-PCR. Key PCR primers used in this study were listed in 
Table 9. PCR was performed in a 50 μl mixture containing each deoxynucleotide 
triphosphate at a concentration of 200 nM, each primer at a concentration of 200 nM, 2.0 
nM MgCl2, 50ng of C. jejuni genomic DNA, and 2.5 U of Platinum Taq DNA 
polymerase (Invitrogen). Real-time quantitative RT-PCR was performed as described 
previously (Guo et al. 2008) using gene specific primers.  
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        Isogenic mutants construction and complementation in trans. To construct 
isogenic Cj0035c (a putative efflux pump gene) mutant of JL341, genomic DNA of 
Cj0035c isogenic mutant of 81-176 (Ge et al. 2005) (Table 8) was extracted and used for 
natural transformation with JL341 as a host strain, creating mutant JL377 with insertional 
inactivation in Cj0035c. 
 Isogenic Cj1125c and Cj1687 mutants of JL341 were constructed by insertional 
mutagenesis as described in a previous publication (Lin et al. 2005). Briefly, to construct 
Cj1125c isogenic mutant of JL341, an approximately 1.7-kb fragment was PCR 
amplified from genomic DNA of JL341 using primer pairs of Cj1125cF and Cj1125cR 
(Table 9). The PCR product was cloned into pGEM T-easy vector (Promega), resulting in 
construct pCj1125c. The chloramphenicol (cm) resistance gene cassette was PCR 
amplified from plasmid pUOA18 (Wang et al. 1990) using  pfu polymerase (Stratagene) 
and primers CmAfeI-F and CmAfeI-R (Table 9). The resulting blunt-ended PCR product 
was purified and ligated into pCj1125c vector, which was digested with SwaI prior to 
ligation, to generate mutant construct pcmCj1125c. The construct pcmCj1125c, which 
serves as a suicide vector, was introduced into JL341 by natural transformation (Van 
Vliet et al. 1998). One transformant designated as JL416 was selected on MH agar plate 
containing 5 μg/mL of chloramphenicol and the insertion of Cm-resistant cassette was 
confirmed by PCR using the specific primers Cj1125cF and Cj1125cR (Table 9). 
Similarly, to construct the isogenic Cj1687 mutant of JL341, primers Cj1687-F and 
Cj1687-R (Table 9) were used to amplify a 2.0-kb fragment from genomic DNA of 
JL341 using Taq polymerase. The PCR product was cloned into a pGEM T-easy vector, 
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resulting in the pCj1687 plasmid. The plasmid was then digested by SwaI and ligated to 
the PCR product of the Cm-resistant gene cassette as described above, generating 
plasmid pcmCj1687. The pcmCj1687 served as a suicide vector to generate an isogenic 
Cj1687 mutant in the JL341 background as described above. The Cj1687 mutation in 
JL372 was confirmed by PCR using the specific primers Cj1687-F and Cj1687-R (Table 
9). A similar site-directed approach was used to create isogenic Cj0630c (DNA 
polymerase III, delta subunit) and Cj1116c (a putative membrane bound zinc 
metallopeptidase) mutants of JL341. 
           To complement perR mutation in K15A2, an 81-176 derivative obtained by 
random transposon mutagenesis, the complete perR gene together with its 200 -bp 
upstream and 100 -bp downstream regions was amplified using PerRF and PerRR 
primers (Table 9) in conjunction with  Pfu polymerase (Stratagene). The blunt -ended 
PCR product was purified and ligated to the SmaI–digested shuttle vector pRY111 (Yao 
et al. 1993). The ligation mixture was then introduced into E.coli DH5α, creating 
construct JL402. The pPerR plasmid from JL402 was transferred into K15A2 by 
triparental conjugation using DH5α/pRK2013 as a helper strain (Akiba et al. 2006). The 
complemented strain JL412 was tested for BCN susceptibility together with other related 
strains. To complement the cmeB mutation in JL360 (JL341 background),  the plasmid 
pCME bearing cmeABC operon (Lin et al. 2003) was extracted and transferred into JL360 





          Prevalence of BCN resistance in C. jejuni and C. coli isolates from various 
source. Total of 137 C. jejuni and 20 C. coli isolates were subjected to susceptibility test 
for BCN OR-7 and E-760. As shown in Fig 2, all C. jejuni isolates were susceptible to 
both OR-7 and E-760 with MICs ranging from 0.25 to 1.0 μg/ml. C. coli appeared to 
display higher intrinsic BCN resistance than C. jejuni with majority of C. coli showing 
MIC ≥ 1 μg/ml. Only one C. coli human isolate, designated as JL106, was resistant to 
both OR-7 and E-760 with MIC of 64 μg/ml. 
          Frequency of emergence of BCNr resistant Campylobacter in vitro. Three C. 
jejuni strains (NCTC 11168, 81-176, S3B) and two C. coli isolates (JL20, JL25) that 
displayed the same MIC of BCN OR-7 (0.5 μg/ml) were chosen for examination of 
frequency of in vitro emergence of BCN resistance. As shown in Table 10, BCNr mutants 
were not obtained using C. jejuni strains under the tested selection pressures.  In contrast, 
C. coli strains displayed higher frequencies of emergence of BCN resistance (1.5x10-8 to 
8.7x10-7) in the presence of different concentrations of OR-7 by a single-step selection; 
the MICs of selected BCNr mutants ranged from 8 to 32 μg/ml.  
The acquired BCN resistance could be transferred at intra- and inter-species 
levels in Campylobacter. C. jejuni and C. coli are well-known for the exceptional ability 
to acquire exogenous DNA by natural transformation, which is considered a major 
mechanism mediating horizontal transfer of antibiotic resistance in Campylobacter. Thus, 
we examined if natural transformation contributes to horizontal transfer of BCN 
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resistance in Campylobacter. Genomic DNA of C. coli JL106 (clinical isolate, MIC = 64  
μg/ml) and JL349 (obtained from above one-step selection in vitro, MIC = 32 μg/ml) 
were extracted and transferred into several C. jejuni and C. coli strains by natural 
transformation. As shown in Table 11, the acquired BCN resistance in C. coli JL349 
could be transformed to C. coli isolates such as JL20 and JL25 with transformation 
frequency about 4x10-7 CFU/μg DNA/recipient cell. Interestingly, the BCN resistance of 
JL106 and JL349 also could be easily transferred into different species such as C. jejuni 
81-176 and NCTC 11168 with transformation with frequency of 10-8 CFU/μg 
DNA/recipient cell. The MICs of BCN for the selected BCNr transformants were up to16 
μg/ml (Table 11).  
Transcriptional profiling of BCNr mutant JL341. DNA microarray analysis 
was performed to compare the transcriptome of the BCNr mutant JL341 to that of its 
parent strain NCTC 11168. The microarray analysis revealed that 9 genes were up-
regulated and 10 genes were down-regulated in BCNr mutant JL341 (Table 12). Since up-
regulation of some genes such as those involved in LPS modification and peptide 
degradation is a common mechanism used by enteric pathogens to confer resistance to 
AMPs (Yeaman et al. 2003), the up-regulated genes from this microarray analysis are of 
particular concern, which include those encoding multidrug efflux pump CmeABC, 
putative drug efflux pump Cj1687 and Cj0035c belonging to a major facilitator super 
family, putative membrane bound zinc metallopeptidase Cj1125c, galactosyltransferase 
PglA, and a putative DNA polymerase III Cj0630c (Table 12).  Up-regulation of these 
genes was also confirmed by qRT-PCR using specific primers as described previously 
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(Guo et al. 2008) (data not shown). The overexpression of CmeABC in JL341 was further 
confirmed by a β-galactosidase promoter fusion assay and immunoblotting using specific 
blotting antibodies against CmeB and CmeC as described in our previous publication 
(Lin et al. 2002) (data not shown). 
 The isogenic cmeB, Cj0035c, Cj1125c, and Cj1687 mutants of JL341 were 
obtained using natural transformation or site-directed mutagenesis.  However, our 
extensive efforts to construct isogenic Cj0630c (DNA polymerase III) and Cj1116c 
(membrane Zn metallopeptidase) mutants of JL341 were unsuccessful, probably due to 
the essential role of these gene products in Campylobacter growth. Except for the cmeB 
mutant, none of the generated isogenic mutants (Cj0035c, Cj1125c, and Cj1687) 
displayed increased susceptibilities to OR-7. Inactivation of cmeB in JL341 led to 4-fold 
MIC reduction for BCN OR-7 (Table 13). Complementation of the cmeB mutant with 
pCME plasmid fully restored MIC back to the level of the parent strain (Table 13). To 
test if CmeABC contributes to intrinsic resistance of C. jejuni NCTC 11168 to BCN, the 
isogenic cmeB mutant was compared to wild-type strain for susceptibility to OR-7. As 
shown in Table 13, inactivation of CmeB in wild-type strain also significantly increased 
susceptibility of the mutant (JL199) to OR-7. To determine whether the BCN resistance 
in JL341 is partly attributed to the overexpression of CmeABC, the cmeR mutant of 
11168, which overexpresses CmeABC (Lin et al. 2005), was also subjected to MIC test. 
Compared to its parent strain, overexpression of CmeABC in JL4 due to cmeR mutation 
led to slight but consistent increase in the MIC of  BCN (1 μg/ml) (Table 13). 
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  Identification of genes contributing to BCN resistance by random transposon 
mutagenesis. A complementary genomic approach to microarray, random transposon 
mutagenesis, was used to identify genes involved in BCN resistance in this study. A 
library containing 2496 Kanr mutants were generated for screening mutants with an 
increased susceptibility to BCN. Six mutants displaying higher susceptibility to BCN 
OR-7 than parent strain JL358 were identified (Table 14). Backcrossing of the transposon 
mutations into the parent strain by natural transformation further confirmed that the 
BCN-sensitive phenotype in each mutant was linked to the gene with a specific 
transposon insertion. Direct sequencing of the mutant genomic DNA using transposon-
specific primers (Lin et al. 2009) revealed a specific transposon insertion site in each 
mutant (Table 14). All the transposon insertions were in coding regions of corresponding 
genes. Five of the six mutants had transposons inserted in different sites of the genes 
encoding the multidrug efflux pump CmeABC, which has been characterized in our 
previous study (Lin et al. 2002). This finding clearly indicated that CmeABC is involved 
in acquired BCN resistance in JL358.  However, the expression level of CmeABC in 
JL358 is comparable to its BCNs parent strain 81-176 as demonstrated by 
immunoblotting and LacZ-promoter fusion assay (data not shown). Similar to the finding 
in NCTC 11168 (Table 13), inactivation of CmeABC in 81-176 also led to increased 
susceptibility to OR-7 (4-fold MIC reductions) (data not shown).  
The remaining mutant K15A2 has a transposon insertion in perR, a gene encoding 
the Fur family regulator. Complementation of perR mutation in K15A10 (construct 
JL412) partially restored BCN resistance to 8 μg/ml for OR-7. In addition, inactivation of 
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PerR in wild type C. jejuni 81-176 resulted in increased susceptibility to OR-7 (2-fold 
MIC reduction), indicating that PerR is also involved in intrinsic resistance to BCN. 
DISCUSSION 
The comprehensive survey in this study using Campylobacter strains from various 
origins and geographically diverse regions provides more compelling evidence 
demonstrating the potent killing activity of BCNs OR-7 and E-760 against 
Campylobacter, which has been shown in previous publications (Svetoch et al. 2005; 
Svetoch et al. 2008). The survey also clearly indicated that BCN Campylobacter is rarely 
detected in clinical and environmental isolates, suggesting that Campylobacter has 
difficulty developing BCN resistance in hosts even if Campylobacter may frequently 
encounter various BCNs produced by commensals in the intestine (Svetoch et al. 2005; 
Svetoch et al. 2008). The finding from this survey is consistent with the examination of in 
vitro emergence of BCNr Campylobacter described in this study (Table 10), in which no 
BCNr C. jejuni mutants were selected under selection pressure while only C. coli mutants 
could develop BCN resistance in vitro with all mutants only displaying low-level 
resistance to BCN. Although it is still unknown why C. coli develops BCN resistance 
more easily than C. jejuni, our findings strongly suggest that there is less in the way of 
resistance development for the anti-Campylobacter BCNs, such as OR-7 and E-760. 
These findings support a recent theory that bacteria have not developed highly effective 
mechanisms to resist BCNs and other endogenous AMPs during evolution, which is 
likely due to multiple activities of natural AMPs (Peschel et al. 2006). The best studied 
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BCN is nisin which is ribosomally produced by Lactococcus lactic. Nisin exerts 
bactericidal effects via at least two modes of action: targeting the membrane-bound cell 
wall precursor lipid II, consequently resulting in inhibition of peptidoglycan synthesis, 
and membrane pore formation resulting in membrane damage and depolarization (Hasper 
et al. 2006). Resistance to nisin has been reported in some bacteria (Margolles et al. 2006; 
Sun et al. 2009); however,  high levels of nisin resistance in bacteria  were not observed 
in bacteria eventhough it has been used as a food preservative for a half century 
(Enserink 1999). It has been also reported that the acquired bacterial resistance to BCNs, 
such as pediocin PA-1 and nisin A, is unstable and has associated with a fitness cost 
(Gravesen et al. 2002). The stability of the acquired resistance to anti-Campylobacter 
BCNs in Campylobacter is still unknown and needs to be examined in future studies.  
AMPs including various BCNs have been considered potential natural ‘peptide 
antibiotics’ to combat bacterial infections (Hancock 1997; Ennahar et al. 2000; Cotter et 
al. 2005; Asaduzzaman et al. 2009). Elucidating the underlying mechanisms of AMP 
resistance in bacteria could help us to develop ‘smarter’ antibiotics (Peschel et al. 2006). 
Therefore, in this study, we also determined genetic loci involved in BCN resistance in 
Campylobacter using complementary genomic approaches. Both microarray and random 
transposon mutagenesis demonstrated the role of the multidrug efflux pump CmeABC in 
resistance of Campylobacter to BCN OR-7. Active extrusion of antimicrobials by 
multidrug resistant (MDR) efflux pumps plays vital roles in antimicrobial resistance in 
many Gram-negative bacteria (Poole 2000). It has been observed that MDR efflux pumps 
are also involved in AMP resistance in several bacteria (Yeaman et al. 2003; Tzeng et al. 
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2005; Otto 2009). The best studied bacterium is Neisseria gonorrhoeae whose multidrug 
efflux pump mtrCDE contributes to both intrinsic and acquired AMP resistance; 
overexpression of MtrCDE mildly increased resistance to human AMPs (2 to 4 fold 
increase in MIC) (Shafer et al. 1998). In Campylobacter, the CmeABC MDR efflux 
pump contributes to resistance to various antimicrobials, including both structurally 
diverse antibiotics and natural antimicrobials present in the intestine, such as bile salts 
(Lin et al. 2002; Lin et al. 2003; Yan et al. 2006). In this study, we observed that 
CmeABC also contributes to both intrinsic and acquired BCN resistance in 
Campylobacter. Notably, the findings from this study indicated that involvement of 
CmeABC in BCN resistance does not require overexpression of CmeABC although 
overexpression of CmeABC could lead to increased BCN resistance. Together, this study 
provides further evidence explaining why CmeABC is essential for Campylobacter 
colonization in the intestine (24) and further highlighting the multi-function nature of 
CmeABC and critical role of CmeABC in Campylobacter pathobiology. 
Although CmeABC plays an important role in BCN resistance,  inactivation of 
CmeABC alone in the BCNr strain JL360 did not lead to a susceptibility level comparable 
to its parent strain JL241 (Table 13), strongly suggesting that other factors work together 
with CmeABC to contribute to the acquired BCN resistance observed in JL360.  Based 
on microarray work in this study, several up-regulated genes are of particular interest. In 
addition to the putative efflux transporters Cj1687 and Cj0035c, Cj1116c, a putative 
peptidase, may involve proteolytic cleavage of BCNs because degradation of AMPs by 
protease is one of mechanisms used by bacteria to resist endogenous AMPs (Yeaman et 
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al. 2003). In Salmonella, the membrane protease PgtE, which is regulated by the two 
component regulatory system PhoP/PhoQ, is responsible for degrading cationic AMPs 
(Guina et al. 2000). The zinc-dependent membrane metalloprotease ZmpA and ZmpB in 
B. ennocepacia degrade antimicrobial peptides protamin and human cathelicidin LL-37 
as well as other alpha helical cationic AMPs (Kooi et al. 2009). The PglA (Cj1125c) is a 
galactosyltransferase that is involved in N-linked protein glycosylation, a unique surface 
carbohydrate modification mechanism that was observed in C. jejuni (Linton et al. 2005); 
such surface modification may be required for BCN resistance in Campylobacter. In this 
study, we have successfully obtained mutants with mutations in most of these interested 
genes. However, none of these mutants displayed increased susceptibilities to BCN 
compared to their parent strain JL341. We were not able to generate a mutation in 
Cj1116c, strongly suggesting that Cj1116c is an essential gene for Campylobacter 
physiology. Additional work, such as production and purification of recombinant 
Cj1116c, are needed to determine whether Cj1116c could function as a peptidase to 
degrade the anti-Campylobacter BCNs. 
Random transposon mutagenesis also identified another gene perR that is 
involved in BCN resistance. PerR is a transcriptional regulator controlling transcription 
of genes encoding oxidative stress resistance proteins (such as catalase KatA, superoxide 
dismutase SodB, and alkyl-hydroxyperoxidase AhpC) (Palyada et al. 2009). 
Transcriptional profiling analysis of an isogenic perR mutant identified 104 genes that 
belong to the PerR regulon (Palyada et al. 2009). PerR activates several genes encoding 
proteins responsible for capsule biosynthesis, which include acetyl-CoA carboxylase 
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AccA, 3-oxoacyl-synthase FabH, and fatty acid/phospholipid synthesis protein PlsX 
(Palyada et al. 2009). Thus, inactivation of perR in BCNr JL358 may affect capsule 
synthesis and such surface remodeling may increase the susceptibility of JL358 to the 
BCN OR-7.  This speculation needs to be examined in the future. 
The results obtained from this study provide helpful information for risk 
assessment of on-farm control of Campylobacter using anti-Campylobacter BCNs, and 
represent the first and major step forward in understanding the genetic mechanisms of 
Campylobacter resistance to BCNs. We have observed that Campylobacter can develop 
low-level BCN resistance in vitro. Clinical survey also suggests that Campylobacter may 
develop BCN resistance at very low frequency in the host. However, it is unknown if 
higher selection pressure (e.g. therapeutic usage of bacteriocins) will promote emergence 
of BCNr Campylobacter mutants in vivo. If so, can Campylobacter develop high-level 
bacteriocin resistance in response to therapeutic treatment with BCN? In addition, it is 
unclear if the BCNr Campylobacter can persist in the absence of selection pressure. To 
obtain solid answers to these questions, multiple laboratory experiments using chickens 
should be performed to examine the dynamic changes of the Campylobacter population 
in response to BCN treatment and to determine in vivo stability of BCN resistance in 
Campylobacter. These studies are expected to provide important information that may 
help avoid a rapid loss of efficiency of BCN and to design more sustainable and ‘smarter’ 
peptide antibiotics. In addition, examination of the molecular basis of BCN resistance in 
Campylobacter may help us to develop more sustainable and effective BCN-based 
intervention strategies against Campylobacter colonization in chickens. In this study, we 
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revealed that active transport of multidrug efflux pump CmeABC confers resistance to 
BCN in Campylobacter. Thus, inhibition of this pump by efflux pump inhibitors will 
significantly increase susceptibility of Campylobacter to BCN. Previous studies (Lin et 
al. 2006; Hannula et al. 2008) have shown that inhibition of efflux pump CmeABC in 
Campylobacter spp resulted in increased susceptibility to various antimicrobials. 
Notably, such an efflux pump inhibitor also could dramatically increase Campylobacter 
susceptibility to intestinal bile salts by inhibiting CmeABC, leading to reduced 
colonization of Campylobacter in chickens (Lin et al. 2006; Hannula et al. 2008). 
Therefore, oral administration of the anti-Campylobacter BCNs together with such efflux 
pump inhibitors using an appropriate delivery system (e.g., encapsulation) would enhance 
the therapeutic effect of anti-Campylobacter BCNs. This speculation needs to be 





















JL106 C. coli strain isolated from human Human a 
JL20 C. coli strain isolated from pig This study 
JL349 JL 20 derivative, BCNr mutant obtained from single step 
selection in vitro 
This study 
JL241 C. jejuni NCTC 11168 strain isolated from human (Parkhill et al. 2000) 
JL28 C.jejuni 81-176 isolated from human (Black et al. 1988) 
JL199 NCTC 11168 derivative, cmeB::kan (Lin et al. 2005) 
JL341 NCTC11168 derivative, BCNr  mutant generated by natural 
transformation using genomic DNA of C. coli JL106 
This study 
JL4 NCTC 11168 derivative, cmeR::cm  
JL360 JL341derivative, cmeB::kan This study 
JL199 NCTC 11168 cmeB::kan (Lin et al. 2002) 
JL424 JL360 containing shuttle vector pCME This study 
JL416 JL341derivative, Cj1125c::cm This study 
JL372 JL341derivative, Cj1687::cm This study 
JL3 81-176 derivative, cmeB::kan (Lin et al. 2002) 
JL219 81-176 derivative, Cj0035c::cm (Ge et al. 2005) 
JL377 JL341derivative, Cj0035c::cm This study 
JL358 81-176 derivative, BCNr mutant generated by natural 
transformation using JL349 genomic DNA 
This study 
K15A2 JL358 perR::kan This study 
JL412 K15A2/pPerR This study 
Plasmids 
pGEM-T Easy  PCR cloning vector, Ampr Promega 
pCj1125c  pGEM-T Easy containing 1.7 kb Cj1125c gene of JL241 This study 
pcmCj1125c  pCj1125c with Cm resistance gene inserted in Cj1125c gene This study 
pCj1687  pGEM-T Easy containing 2.0 kb Cj1687 gene of JL241 This study 
pcmCj1687  pCj1687 with Cm resistance gene inserted in Cj1687 gene This study 
pRY111  E.coli-C.jejuni shuttle vector, cmr (Lin et al. 2002) 
pPerR  pRY111 derivative containing a 1.45-kb perR gene plus its 
promoter region 
This study 
pCME  pUOA18 shuttle vector derivative containing a wild-type 
cmeABC operon 
(Lin et al. 2003) 
pRK2013 IncP Tra RK2+ repRK2 repE1+, Kanr (Ditta et al. 1980) 
E.coli    
DH5α F– 80lacZ M15 (lacZYA-argF)U169 recA1 endA1 
hsdR17 (rk–, mk+) phoA supE44 thi-1 gyrA96 relA1 – 
Invitrogen 
JL402 E.coli DH5α containing  pPerR  This study 
JL48 Conjugation helper strain, DH5α containing plasmid RK2013 (Akiba et al. 2006) 
 





Table 9.  Key oligonucleotide primers used in this study (Chapter III) 
 
Primer DNA Sequences (5’ - 3’) a Product size 
 
Gene amplified 
    
Cj1125cF GCCCGCTAGAATGTCTTTGA 1733 Cj1125c 
Cj1125cR ATCTAACCCGGGACGATTTT   
Cj1116cF GGAACTCATTGATGAAATGCAA 1982 Cj1116c 
Cj1116cR CCCTACCATCTATAGGTGCAAAA   
CmAfeI-F GCGAGCGCTTGCTCGGCGGTGTTCCTTT 
 




Cj1687F1 TCTTTGGCATCTTTGGCTTT 2000 Cj1687 
Cj1687R1 TGCGATTTTGATGTTTCC   
Cj0630cF CAACGAAAAACAAAGCAA 1350 Cj0630c 
Cj0630cR TGTTTTTAAGTTCTTCGATTTTTGC   
PerRF2 AAACAAGTAAGGTGGAA 1662 Cj0032 (perR) 
PerRR2 AGTGCAATCAGATAGTAAA   
     
a Restriction sites are underlined in the primer sequences 
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 (μg /mL) 
Frequency of emergence of BCN resistance for each straina 
C. jejuni C. coli 
 81-176 11168      S3B JL20 JL25 
4 <9.2x10-9 <2x10-10 <1.5x10-10 (3.5 ± 1.0)x10-7 (8.7 ± 5.6)x10-7 
8 <9.2x10-9 <2x10-10 <1.5x10-10 (1.8 ± 1.6)x10-7 (1.1 ± 1.0)x10-7 
16 <9.2x10-9 <2x10-10 <1.5x10-10 (1.5 ± 1.4)x10-8 (1.7 ± 1.4)x10-8 
 
a The values are means of two independent experiments with triplicate measurements. 
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C. coli JL106 
(MIC = 64) 
C. jejuni  
NCTC11168 
1.2 x10-8 8 (JL341) 
C. coli JL349 
(MIC = 32) 
C. jejuni 81-176 1.0 x10-8 16 (JL358) 
C. coli JL20 4 x10-7 16 
C. coli JL25 4 x10-7 16 
 
a The values are from a representative experiment with duplicate measurements within 
each independent experiment. 
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Table 12. Differentially expressed genes ( ≥ 2-fold change) in NCTC 11168 BCNr mutant 
JL341 identified by microarray 
 







Inner membrane transporter of CmeABC efflux system 4.9 5.93E-06 
Cj0365c 
(cmeC) 
Outer membrane component of CmeABC efflux system 4.0 2.72E-05 
Cj0630c DNA polymerase III, delta subunit 13.5 4.63E-04 
Cj1726c Putative homoserine O-succinyltransferase 2.0 8.31E-04 
Cj1116c Putative membrane bound zinc metallopeptidase 4.8 4.00E-03 
Cj1125c  Putative galactosyltransferase (wlaG/pglA) 12.8 5.50E-03 
Cj0176c Putative lipoprotein 2.0 7.05E-03 
Cj1687 Putative efflux transporter (MFS family) 2.0 2.14E-02 
Cj0035c Putative efflux transporter (MFS family) 3.4 2.19E-02 
Down-regulated genes 
Cj0508  Penicillin-binding protein -4.5 2.37E-05 
Cj0093 Putative periplasmic protein -2.5 1.49E-04 
Cj0628 Putative lipoprotein -2.9 1.57E-04 
Cj0045c Putative iron-binding protein -2.0 6.60E-04 
Cj0091 Putative lipoprotein -2.5 8.90E-04 
Cj0629 Putative lipoprotein -2.7 1.16E-03 
Cj1423c Putative sugar-phosphate nucleotidyltransferase -2.7 1.49E-03 
Cj1650 Hypothetical protein -17.9 1.80E-03 
Cj1714 Small hydrophobic protein -2.4 4.56E-03 





Table 13. CmeABC contributes to both intrinsic and acquired BCN resistance in C. jejuni 
NCTC 11168 
 
Strains Description MICs of OR-7 (µg/ml) 
JL241 Wild type NCTC 11168 0.5 
JL199 NCTC 11168 derivative, cmeB::kan 0.125 
JL4 NCTC 11168 derivative, cmeR::cm 1 
JL341 NCTC 11168 derivative, BCNr mutant 8.0 
JL360  JL341 derivative, cmeB::kan 2 




Table 14.  Identification of transposon mutants with increased sensitivity to BCN 
compared to MIC of 16 μg/ml for parent strain JL358 
 






(ORF size, bp)a 
Function of inserted gene 
product 
K15A2 4 Cj0322 (perR) 54 (411) Fur family regulator 
K17E10 4 Cj0367c (cmeA) 557(1104) Component of CmeABC pump 
K16H6 4 Cj0366c (cmeB) 790(3123) Component of CmeABC pump 
K11A10 4 Cj0365c (cmeC) 107(1479) Component of CmeABC pump 
K1H1 4 Cj0366c (cmeB) 1679(3123) Component of CmeABC pump 
K15G10 4 Cj0365c (cmeC) 1213(1479 Component of CmeABC pump 
 
aThe number indicates the nucleotide before which the transposon (Tn) is inserted.  




Figure 2. Prevalence of Campylobacter spp isolates resistance to bacteriocin. 137 C. 
jejuni and 20 C. coli isolates were examined for the susceptibility to BCN OR-7 and E-








































Bacteriocins (BCNs) are antimicrobial peptides produced by bacteria with narrow 
or broad ranges of antimicrobial activity. Recently, several unique anti-Campylobacter 
BCNs have been identified in commensal bacteria isolated from chicken intestines. These 
BCNs dramatically reduced C. jejuni colonization in poultry and are being directed 
toward on-farm control of Campylobacter. Our previous study in Chapter III 
demonstrated that Campylobacter could develop resistance to BCNs in vitro. However, 
no information exists concerning in vivo development and stability of BCN resistance in 
Campylobacter, an important issue needing to be addressed for practical application of 
BCN-based intervention measures. In this study, development and stability of BCN 
resistance were examined. For the in vivo development of BCN resistance, chickens that 
have been colonized by C. jejuni NCTC 11168 were fed with BCN E-760 at dose of 5 
mg/kg body weight for three consecutive days. For in vivo stability of BCN resistance, 
groups of chickens were fed one of three BCNr Campylobacter strains obtained from 
different sources. Total and BCNr C. jejuni populations in fecal samples from both 
studies were determined by differential plating using selective plates with or without 
BCN E-760. In addition, in vitro stability was tested by repeated subculturing of the 
BCNr mutants in BCN E-760-free broth medium followed by differential plating. Our 
results showed that C. jejuni could develop resistance to BCN in vivo. However, the 
BCNr mutants only accounted for 0.0005% of the total C. jejuni population in the feces. 
MIC tests indicated all mutants displayed low-levels of resistance to E-760 with MIC 
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values ranging from 2 to 8 µg/ml. Inactivation of the CmeABC efflux pump of the BCNr 
mutants led to increased susceptibility to E-760. The low-level of BCN resistance was not 
stable in vivo, and BCNr mutants were not detected at day 42 after inoculation. BCN 
resistance was also not stable after 10 passages in vitro; more than 95% of BCNr 
Campylobacter spp were sensitive to the BCN after 35 passages. This study highlights 
the significance of in vivo usage of BCN for Campylobacter control in poultry. BCN 
selected only low-level BCNr C. jejuni mutants in vivo and the low-level BCN resistance 




Campylobacter species, the epsilon class of proteobacteria, are the leading 
bacterial causes of human gastroenteritis in developed countries (Allos 2001). In addition 
to watery diarrhea and/or hemorrhagic colitis, infection with Campylobacter spp can 
result in post-infectious manifestations such as Guillain-Barre’ syndrome, an acute 
immune mediated disorder that may lead to respiratory muscle compromise and death 
(Nachamkin et al. 1998). Campylobacter spp are considered to be commensal organisms 
in the intestinal tract of wild and domestic animals including chicken and other avian 
species (Diker et al. 2000). Epidemiological studies demostrated that consumption of 
contaminated poultry meat is the major cause of human campylobacteriois (Stern et al. 
2001; Cox et al. 2002; Stern et al. 2004). Thus, on-farm control of Campylobacter spp 
could reduce risk of human Campylobacter infection. Of the several proposed strategies 
to reduce this risk, anti-Campylobacter bacteriocins (BCNs) are considered a promising 
strategy to protect food safety and public health (Lin, 2009). 
BCNs are short cationic antimicrobial peptides naturally produced by diverse 
microbes in different environments (Willey et al. 2007). Despite significant structural and 
characteristic differences, BCNs display potent antimicrobial activities against a wide 
range of viruses, bacteria, and fungi with diverse modes of action and have been 
recognized as a novel class of antimicrobials to control foodborne pathogens (Hugas et al. 
1998; Zasloff 2002; Galvez et al. 2007; Settanni et al. 2008). As a group of natural 
antimicrobials, some BCNs, such as nisin, have long been applied for food preservation.  
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More than 99 percent of bacteria including intestinal commensals can make at least one 
bacteriocin (Klaenhammer 1988; Riley et al. 1992). Therefore, intestinal BCN-producing 
bacteria may achieve a competitive advantage and function as an innate barrier against 
pathogens in the hosts. The natural BCNs have been proposed as promising candidates 
for novel antimicrobials (Joerger 2003; Asaduzzaman et al. 2009). 
Several anti-Campylobacter BCNs were successfully isolated and characterized 
from chicken commensal bacteria, which includes OR-7 from Lactobacillus salivarius 
(Stern et al. 2006), E-760 and E50-52 from Enterococcus faecium (Line et al. 2008; 
Svetoch et al. 2008), and SRCAM from Paenibacillus polymyxa (Stern et al. 2005). 
Animal studies have demonstrated that these BCNs dramatically reduced C. jejuni 
colonization in the intestine and these BCNs are being developed toward on-farm control 
of Campylobacter to protect public health. Although the anti-Campylobacter BCNs are 
very effective in reducing C. jejuni colonization in poultry, several important issues (e.g. 
production, safety, and development and stability of resistance) need to be addressed for 
future regulatory approval and public acceptability of this intervention measure. The 
study in chapter III has demonstrated that Campylobacter could develop low-level BCN 
resistance in vitro.  However, no information exists concerning in vivo development and 
stability of BCN resistance in Campylobacter. Using both in vitro and in vivo systems, 
we showed the in vivo usage of BCN selected only low-level BCNr C. jejuni mutants and 
the low-level BCN resistance was not stable under both in vitro and in vivo conditions. 
This study provides helpful information for risk assessment of the future practical 
application of the anti-Campylobacter BCNs in poultry. 
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MATERIALS AND METHODS 
Bacteriocin E-760, bacterial strains and growth conditions.  Bacteriocin E-760 
(Line et al. 2008) was kindly provided by Dr. Norman J. Stern (USDA/ARS). E-760 was 
dissolved in distilled water and stored at -200C prior to use. The major bacterial strains 
used in this study are listed in the Table 15. All strains were routinely grown in MH broth 
or agar at 420C under microaerophilic conditions generated using a CampyGen Plus gas 
pack (Oxiod, Lenxa, KS) in an enclosed jar. When needed, E-760 was added in MH agar 
at desired concentrations. 
in vivo development of BCN resistance in Campylobacter. The in vivo 
development of BCN resistance in Campylobacter was examined using a chicken model 
system. In this experiment, day-old broiler chicks (a kind gift from commercial company 
Hubbard Hatchery, Pikeville, TN) were randomly assigned to either treatment (10 chicks) 
or control groups (10 chicks). All birds were placed in sanitized wire cages with 
unlimited access to feed and water. Nutritionally complete feed was prepared in the feed 
mill at the Johnson Animal Research and Teaching Unit, the University of Tennessee. 
Prior to inoculation with C. jejuni NCTC 11168, all birds were confirmed to be free of 
Campylobacter by culture of cloacal swabs. At 2 days old, all birds in treatment and 
control groups were inoculated with fresh C. jejuni NCTC 11168 cultures (107 CFU/bird) 
via oral gavages. Three days after Campylobacter inoculation, all birds were examined to 
ensure colonization by Campylobacter. For the treatment group, at 9 days of age, all birds 
were treated with BCN E-760 at the dose of 5 mg/kg body weight/day via oral gavages 
for three consecutive days. Birds in the control group were gavaged with water. Cloacal 
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swabs were collected from all birds in both groups at day 1, 2, 3, 5, and 7 after the initial 
BCN treatment. Samples from each bird were serially diluted and spread onto two 
different plates: MH agar selective supplement (normal selective plates) to recover all 
Campylobacter populations, and MH agar selective supplement plus E-760 with final 
concentration of 16 µg/ml to recover BCN resistant populations. Campylobacter colonies 
were counted following 48 hours of incubation at 420C under microaerophilic conditions. 
Individual colonies from E-760 containing plates were randomly picked to identify level 
of BCN resistance using MIC testing as described below. In addition, representative 
colonies from BCN-free plates were also chosen for MIC test. 
The detection limit of the plating method was approximately 100 CFU/g of feces. 
The significant difference in Campylobacter colonization levels (log10 transformed 
CFU/g of feces) at each sampling point between groups was calculated using Student’s t 
test. A P-value of <0.05 was considered significant. 
in vitro stability of BCN resistance. Three BCN resistant mutants were 
examined for in vitro stability of acquired BCN resistance, which include a human 
clinical isolate JL106 (E-760 MIC = 64 μg/ml), the in vitro-selected mutant JL341 (E-760 
MIC = 8 μg/ml), and the in vivo-selected strain K58 (MIC = 8 μg/ml) (Table 15). Briefly, 
the three strains were inoculated in E-760-free MH broth and grown under 
microaerophilic conditions at 420C. The Campylobacter cultures were sub-cultured every 
2 to 3 days in fresh MH broth (1:400 dilutions) for 70 days in the absence of any 
antimicrobials. Following passages 10, 15, 20, 25, 30, and 35, the cultures were serially 
diluted (10-fold dilutions) in MH broth and plated onto both MH agar plates and MH 
 
 90 
agar plates supplemented with E-760 at a concentration of 16 μg/ml. The plates were then 
incubated in microaerophilic conditions at 420C for two days. Total numbers of colonies 
on each type of plate were counted and compared for each time point. In addition, 
following passage 35 differential plating, 20 colonies for each mutant were randomly 
picked up from bacteriocin-free MH agar plates and were subjected to E-760 MIC test as 
described below. 
in vivo stability of BCN resistance using a chicken model system. The same 
BCN resistant mutants were used for an in vivo stability test using a chicken model 
system. Bird source and maintenance were the same as those used in the in vivo 
development of BCN resistance experiment described above. Forty one-day old chickens 
were randomly assigned into four groups (10 chickens each group). Prior (3 days) to 
inoculation with Campylobacter, all birds were confirmed free of Campylobacter by 
cultured cloacal swabs. Birds in each group received the corresponding Campylobacter 
strain at a dose of 107 CFU/bird via oral gavage at 3 days old. Birds in the control group 
were treated with wild-type, E-760 sensitive strain C. jejuni NCTC 11168.  Birds in the 
other three treatment groups were inoculated with JL106, JL341, and K58, respectively 
(all strains displayed comparable growth level in vitro). Birds in all groups received 
BCN-free feed and water throughout the trial. Cloacal swabs were collected from birds in 
all groups at day 6, 22, and 42 after Campylobacter inoculation. Isolation of 
Campylobacter spp and differential plating for enumerating the proportion of BCN 
resistance mutants in the populations in each group were identified the same as the 
chicken experiment described above. At each time point, representative colonies (40 
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colonies) from chickens in each group were chosen for E-760 MIC test. Multiple isolates 
with different E-760 MICs were analyzed by PCR to confirm their genetic identities. The 
PCR was done using primers specific for the cmp gene encoding the major outer 
membrane protein as described previously by Huang et al. (2005), which revealed no 
difference between input strain and output isolates. 
E-760 susceptibility test. The susceptibility of Campylobacter spp to E-760 was 
determined by standard micro titer broth dilution method with an inoculum of 106 
bacterial cells/ml that was described previously (Lin et al. 2002). Minimum inhibitory 
concentration (MIC) was determined by the lowest E-760 concentration that completely 
inhibited Campylobacter growth after 24 hours under microaerophilic condition at 420C. 
Insertional mutagenesis of the cmeB gene in BCN resistant mutants. To 
construct an isogenic cmeB mutant in Campylobacter in vivo-selected BCN resistant 
mutants, genomic DNA of JL3 (Table 15), a cmeB mutant, was extracted and was used 
for natural transformation by biphasic natural transformation as described previously 
(Davis et al. 2008). 
RESULTS 
Effect of E-760 treatment on the emergence of BCN resistant Campylobacter 
in chickens. In this experiment, all chickens in both groups were successfully colonized 
by C. jejuni NCTC 11168 prior to E-760 treatment. The shedding levels of C. jejuni in 
both groups were similar (approximately 5.5 log10 units). Throughout the trial C. jejuni 
consistently colonized all chickens regardless of BCN treatment (Fig 3). E-760 resistant 
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mutants were selected from one chicken in the BCN treated group one day after the first 
treatment. Six days after the first treatment, 80% of chickens were found to shed E-760r 
mutants (Fig 4). However, the E-760 resistant mutants only accounted for a small portion 
of Campylobacter population in individual chicken (0.0005%). MIC test of 17 randomly 
selected E-760 resistant Campylobacter isolates generated in vivo indicated that mutants 
displayed low-level resistance to E-760 with MIC ranging from 2 µg/ml to 8 µg/ml 
(Table 16). No chickens in the control group shed E-760 resistant mutants. 
CmeABC contributes to E-760 resistance in the in vivo-selected 
Campylobacter isolates. Studies in chapter III have shown the multidrug efflux pump 
CmeABC contributed to both intrinsic and acquired BCN resistance in Campylobacter. 
However, it is unknown if CmeABC plays a role in E-760 resistance in the in vivo-
selected mutants obtained from this study. As shown in Table 16, regardless of resistance 
level of a specific mutant, inactivation of cmeB significantly reduced E-760 MIC to 0.125 
µg/ml, which is lower than the E-760 MIC for the wild-type strain NCTC 11168.  
Bacteriocin E-760 resistance is not stable in vitro in the absence of BCN 
selection pressure. As shown in Fig 5, less than 10% of JL341 populations could be 
selected on MH agar plates containing 16 µg/ml of E-760 after 10 passages in the 
absence of BCN selection pressure. Following 35 passages, only a very small population 
of JL341 (0.0005%) were recovered on an E-760-containing plate. Although JL106 and 
K58 showed higher stability than JL341 in vitro, less than 0.1% and 1% of JL106 and 
K58, respectively, were selected on BCN-containing plates after 35 passages. The 
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differential plating results were also confirmed by E-760 MIC tests of representative 
colonies selected after 35 passages (data not shown).  
in vivo instability of E-760 resistance in Campylobacter. All chickens were 
successfully colonized by Campylobacter in both control (C. jejuni NCTC 11168) and 
treatment groups inoculated with C. jejuni JL341, K58, or  C. coli JL106 with shedding 
levels of approximately 7 log10 units per gram feces at 6 days post inoculation (Fig 6A). 
Unexpectedly, the percentage of chickens colonized with E-760 resistant strains 
decreased after 22 days (JL106) and 42 days (JL341, K58, and JL106) of inoculation 
(Table 17). The shedding levels of Campylobacter in colonized chickens were also 
slightly reduced in both control and treatment groups at 22 and 42 days postinoculation 
when compared to 6 days postinoculation (Fig 6A). 
The in vivo stability of BCN resistance was monitored by differential plating as 
well as E-760 MIC tests of randomly selected colonies (40 colonies per time point per 
group). As showed in Fig 6B, percentage of E-760 resistant mutants decreased for all 
three Campylobacter strains with time. By 42 days post inoculation, E-760 resistant 
populations were less than 7% for all three resistant strains. The resistance levels were 
also reduced to < 2 µg/ml for randomly selected resistant colonies (data not shown).  
DISCUSSION 
Several anti-Campylobacter BCNs have been successfully identified and 
characterized from chicken commensal bacteria (Stern et al. 2005; Svetoch et al. 2005; 
Stern et al. 2006; Line et al. 2008; Svetoch et al. 2008). Feeding these anti-
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Campylobacter BCNs to poultry pre-slaughter eliminated Campylobacter colonization 
(Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006; Line et al. 2008; Svetoch et al. 
2008). Although these BCNs are very effective in reducing Campylobacter spp 
colonization in poultry, the use of these anti-Campylobacter BCNs may lead to 
emergence of BCN resistant isolates resulting in problems in the treatment of resistant 
Campylobacter infection. Therefore, studying BCN resistance including development and 
stability of resistance are crucially important for future regulatory approval and public 
acceptability of this intervention measure. In our previous study discussed in Chapter III, 
we demonstrated that Campylobacter spp could develop low levels of BCN resistance in 
vitro. In this study, we examined the in vivo development BCN resistance in 
Campylobacter using a chicken model system. Because BCNs have been proposed to be 
fed to chickens for three consecutive days pre-slaughter to control Campylobacter (Cole 
et al. 2006), a treatment regimen mimic clinical (3 consecutive days) with BCN was 
applied in this study. Our data showed that in response to BCN treatment, BCN resistant 
C. jejuni quickly emerged as early as one day after the first BCN treatment. However, the 
BCN resistance in Campylobacter was low in terms of MIC (1 µg/ml to 8 µg/ml, even 
after the third BCN treatment) and frequency (0.0005%) during the whole experiment. 
This in vivo finding is consistent with the in vitro results described in Chapter III. In vivo 
resistance development of Campylobacter to several antibiotics used as either therapeutic 
or growth promotants has been well studied (Luo et al. 2003; Lin et al. 2007; Han et al. 
2008; Lindow et al. 2010). A previous study (Lin, Yan et al. 2007) showed that 
development of macrolide resistance in vivo was only observed after long-term exposure 
to tylosin. Short-term treatment of Campylobacter-infected chickens with a high dose of 
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macrolide also did not result in selection of Erythromycin resistance. However, long-term 
treatment with a low dose of tylosin in feed resulted in the emergence of resistance 
mutants with high levels of MIC (12 to 100% of tested isolates). The result in this study 
revealed different patterns of resistance development for tylosin and BCN usage.  The 
BCN resistance appears to develop quickly but the MIC resistance levels of the mutants 
are low in Campylobacter. However, the results should be interpreted cautiously because 
the experiment was conducted in a laboratory environment using a small number of 
chickens which does not represent the production conditions in most poultry farms. In 
addition, a dose experiment should be performed to determine if greater selection 
pressure would promote the development of mutants with high-level BCN resistance. 
Finally, antibiotic resistance development on farms is very complex and influenced by 
multiple factors such as animal species, production environment, genetic background of 
bacterial species, and management practices.  
 In addition to demonstrating the development of BCN resistance, we also 
observed dynamic changes in BCN resistance of individual chickens in this study. One 
day after the first treatment, only 10% of the chickens in the treated group were positive 
with BCN resistant Campyloabcter. Then, the number of chickens colonized by 
resistance Campylobacter steadily increased during the course of treatment eventually 
80% of chickens were found positive with BCN resistant Campylobacter two days after 
the third treatment, and quickly dropped to 40% two days afterward (Fig 4). This finding 
showed the 3-day BCN treatment exerted continuous selection pressure and resulted in an 
increased number of chickens shedding BCN resistant mutants by 5 days after the first E-
 
 96 
760 treatment. The resistance in Campylobacter is likely not stable due to fitness cost, 
consequently resulting in clearance of BCN resistant Campylobacter after cessation of 
BCN treatment. These speculations need to be further examined in future studies. 
Multidrug resistance efflux pump CmeABC plays a prominent role in resistance 
to various antimicrobials and chicken colonization (Lin et al. 2002; Lin et al. 2003). It 
was shown in Chapter III that CmeABC contributed to both intrinsic and acquired 
resistance to BCN for the mutants selected in vitro. This result suggests that CmeABC 
plays a role in low level BCN resistance in Campylobacter in both in vivo and in vitro. 
Thus, a combination of anti-Campylobacter BCN and CmeABC pump inhibitors could be 
a feasible approach to eliminate Campylobacter colonization and reduce BCN resistance 
in chickens. 
Antibiotic resistance in bacteria is occurring as the result of either chromosomal 
mutations or horizontal transfer of mobile genetic elements, such as plasmids, phages, 
transposons, and integrons. These genetic changes may influence physiological processes 
in microorganisms. Both chromosomal mutations and plasmid-mediated antibiotic 
resistance, generally result in a fitness cost creating growth impairment and/or less 
decreased competitiveness with antibiotic sensitive strains. The stability of antibiotic 
resistance and fitness cost due to acquisition of antibiotic resistance are unique in 
Campylobacter compared to other microorganisms. Our previous studies demonstrated 
that low levels of macrolide resistance in Campylobacter associated with mutations in 
ribosomal proteins L4 and L22 were unstable in vitro. In contrast, high levels of 
macrolide resistance due to mutations at A2074G and A2075G in 23S rRNA were stable 
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in vitro in the absence of macrolide selection pressure (Lin et al. 2007; Caldwell et al. 
2008). Luo et al. (Luo et al. 2005) reported that fluoroquinolone (FQ) resistance in 
Campylobacter associated with gyrA mutation is very stable in vivo and in vitro, and FQ-
resistance strains did not show any fitness costs. FQ-resistance even enhances ecological 
fitness and outcompetes FQ-sensitive strains when coinoculated in chickens. In our study, 
both in vivo and in vitro experiments clearly showed that BCN resistance was not stable 
regardless of Campylobacter species and resistance levels. This information is also 
important for the risk assessment of using BCN in practical applications. For example, it 
is likely that some BCN resistant Campylobacter mutants may be transmitted to a new 
flock. However, based on the finding from this study, the BCN resistance trait will be lost 
when these mutants colonize new a flock that receives BCN-free feed, consequently 
















Table 15. Major bacterial strains used in this study (Chapter IV) 
Strains Description Source and reference 
JL3 NCTC 11168  derivative, cmeB::kan (Lin et al. 2002) 
JL106 E-760r C. coli; clinical strain isolated from 
 
This study 
NCTC 11168 Human isolate, genome available (Parkhill et al. 2000) 
JL341 NCTC 11168 derivative, E-760r mutant 
generated by transformation using genomic 
   
This study 
K58 NCTC 11168 derivative, E-760r mutant 





Table 16. E-760 MICs of the in vivo-selected E-760r C. jejuni isolates and their isogenic 
cmeB mutants 
 
Strain E-760 MIC (µg/ml)a E-760 MIC of  isogenic cmeB mutant(µg/ml) 
C. jejuni NCTC 11168  0.5 0.125 
E-760r mutants selected 
in vivo  
2 (3) 0.125 
4 (4) 0.125 
8 (10) 0.125 
 




Table 17. Percentage of chickens colonized with Campylobacter spp 
Strains Day 6 (%) Day 22 (%) Day 42 (%) 
NCTC 11168 100 100 100 
JL341 100 100 60 
K58 100 100 60 





Figure 3. Shedding levels of C. jejuni NCTC 11168 in chickens orally gavaged with 
water (control) or BCN E-760 (treatment). In the treatment group, all birds were treated 
with BCN E-760 at 5 mg/kg body weight/day via oral gavage for three consecutive days. 




























Figure 4. Percentage of chicken colonized with E-760 mutants following E-760 
treatment. Each bar represents the percentage of chickens that shed E-760 resistant 















































Figure 5. Stability of E-760 resistance in vitro. Three strains were passed in MH broth 
without E-760 selection pressure as described in Materials and Methods. The percentage 
of BCNr population was calculated based on differential plating using plates with or 




















































































Figure 6. Stability of BCN resistance in vivo. (A) Shedding levels of BCN resistant 
Campylobacter strains in chickens colonized with Campylobacter. Chickens in each 
group (10 birds/group) were inoculated with BCN sensitive strain NCTC 11168, or one 
of E-760 resistant mutants (JL341, K58, or JL106). All chickens received nonmedicated 
feed throughout the study. Each bar represents the mean of log10 CFU/gram feces ± 
standard deviation of Campylobacter colonized chickens in each group; (B) The E-760 
resistance was not stable in vivo. The percentage of BCNr population was calculated 


































IDENTIFICATION AND CHARACTERIZATION OF GENES REQUIRED FOR 








Antimicrobial peptides (AMPs) are critical components of host defense limiting 
bacterial infections at the gastrointestinal mucosal surface. Bacterial pathogens have co-
evolved with host innate immunity and developed means to counteract the effect of 
endogenous AMPs. However, AMP resistance mechanisms are still unknown in C. jejuni, 
an important human foodborne pathogen with poultry as a major reservoir. In this study, 
random transposon mutagenesis and targeted site-directed mutagenesis approaches were 
used to identify genes contributing Campylobacter resistance to fowlicidin-1, a 
representative AMP in chickens. In addition, a chicken experiment was performed to 
determine the role of candidate genes in Campylobacter colonization in the intestine. An 
efficient transposon mutagenesis approach (EZ::TNTM <KAN-2> Transposome) in 
conjunction with microtiter plate screening identified three mutants whose susceptibilities 
to fowlicidin-1 were significantly increased. Backcrossing of the transposon mutations 
into parent strain confirmed that the AMP-sensitive phenotype in each mutant was 
associated with the specific transposon insertion. Direct sequencing showed that these 
mutants have a transposon inserted in the genes encoding the two-component regulator 
CbrR, transporter CjaB, and a putative trigger factor (Tig). Based on the analysis of 12 
Campylobacter genomes, a conserved gene cj1583c displayed high homology (up to 46% 
similarity at the amino acid level) to sap, an AMP resistance gene identified in other 
pathogens. Insertional inactivation of Cj1583c also significantly increased susceptibility 
of Campylobacter to fowlicidin-1 in diverse strain backgrounds.  In vivo administration 
of CbrR, Tig, and SapB mutants showed a reduction in in vivo colonization. Together, 
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these results have defined four C. jejuni genetic loci that will be useful for characterizing 
the molecular basis of Campylobacter resistance to AMPs, a significant knowledge gap 
in Campylobacter pathogenesis. 
INTRODUCTION 
Campylobacter is a major causative agent of human bacterial gastrointestinal 
diseases worldwide (Allos 2001). Campylobacter is commonly found as a commensal 
organism in the digestive tracts of a variety of wild and domestic animals. Commercial 
poultry are considered the major reservoir for human campylobacteriosis (Moran et al. 
2009). Most Campylobacter infections are epidemiologically associated with 
consumption of undercooked poultry meats; the remaining cases are due to other risk 
factors including contaminated milk, water, and direct contact with infected pets (Lin 
2009). To successfully colonize and persist in intestinal tracts of many animals and 
humans, Campylobacter must have evolved a variety of mechanisms to counteract and 
adapt to harsh conditions. Examination of how this important human pathogen adapts to 
and evades host innate immunity may reveal targets for developing novel vaccine and 
therapeutics to prevent and control Campylobacter infections in humans and animal 
reservoirs. 
Endogenous antimicrobial peptides (AMPs) belong to the most ancient and 
efficient components of host defense. Defensins and cathelicidins are two major groups 
of host AMPs that limit bacterial infections at the gastrointestinal mucosal surface (Bulet 
et al. 2004; Wehkamp et al. 2007). Epithelial AMPs, such as β-defensins, have been 
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observed to be induced in human intestinal epithelia upon infection by C. jejuni (Zilbauer 
et al. 2005; Wehkamp et al. 2007). In addition to their significant role in host innate 
defense, AMPs including chicken cathelicidin fowlicidin-1 (F-1) have been increasingly 
recognized as a novel class of antibiotics (peptide antibiotics) to control pathogens (Xiao 
et al. 2006; Bommineni et al. 2007).  It is not surprising that many bacterial pathogens 
have co-evolved with the host and developed means to counteract the effect of AMPs 
(Yeaman et al. 2003; Peschel et al. 2006). Given the wide prevalence and successful 
colonization of C. jejuni in intestinal tracts, C. jejuni should have acquired mechanisms to 
resist AMPs widely present in the host. However, as an important strategy to evade 
killing by innate immunity and by potential peptide antibiotics, AMP resistance 
mechanisms are still largely unknown in C. jejuni.  Availability of this information will 
not only help us to develop more sustainable peptide antibiotics but also provide insights 
into the delicate host-pathogen interactions and reveal novel intervention targets to 
control Campylobacter infections in humans and animal reservoirs. 
 In this study, using chicken host defense peptide F-1 as a model peptide in 
conjunction with random transposon mutagenesis as well as targeted mutagenesis, we 
identified four genetic loci required for F-1 resistance in Campylobacter, which include a 
two-component regulator CbrR, transporter CjaB, a putative trigger factor Tig, and Sap 
that is homologous to the previously described transporter conferring resistance to AMPs 
in other Gram-negative bacteria. Administration in vivo also demonstrated that these 
genes play an important role in the colonization of Campylobacter in the intestine. 
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MATERIALS AND METHODS 
Bacterial strains, plasmids and growth conditions. The major bacterial strains 
and plasmids used in this study are listed in Table 18. Among 174 Campylobacter 
isolates used for testing susceptibility to chicken AMP F-1, 154 isolates were C. jejuni 
and 20 isolates were C. coli. These Campylobacter strains were isolated from different 
hosts and geographically diverse locations. Campylobacter strains were routinely grown 
in MH broth (Difco) or MH agar at 420C under microaerophilic conditions generated by 
using a CampyGen Plus gas pack in an enclosed jar or by using a tri-gas incubator. E. 
coli strains were grown in Luria-Bertani (LB) broth with shaking (250 rpm) or on agar at 
37ºC overnight. Antibiotics Kanamycin (Kan) or Chloramphenicol (Cm) was added in 
medium at a desired concentration when needed. 
AMP susceptibility testing. The susceptibilities of C. jejuni and C. coli isolates 
to the chicken cathelicidin F-1 were determined by a standard microtiter broth dilution 
method with an inocula of 106 bacterial cells/ml as described previously (Lin et al. 2002). 
Minimum inhibitory concentrations (MICs) were determined by the lowest concentration 
of specific antimicrobial showing complete inhibition of bacterial growth after two days 
of incubation at 420C. Chicken cathelicidin F-1A (F-1) (22 amino acids in length with > 
95% purity) was synthesized by Bio-Synthesis (Lewisville, TX). 
in vitro selection of F-1 resistant C. jejuni. F-1 was used as the selective agent to 
obtain spontaneous F-1 resistant mutants in vitro. Briefly, 0.1 ml of Campylobacter cells 
(OD ~1.2) harvested from MH agar plates incubated overnight  were spread on MH agar 
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plates supplemented with different concentrations of F-1 (32 and 64 μg/ml). To increase 
the chance to get F-1 resistant mutants, the C. jejuni cells were also grown and passed 
five times (2-days for one passage) in MH broth containing sub-lethal concentration of F-
1 (4 μg/ml). After five passages, the bacterial cells then were spread on MH plates 
containing a higher concentration of F-1 (64 μg/ml). F-1 resistant mutants were selected 
from the plates after 4 days of incubation at 420C under microaerophilic conditions. All 
these selected mutants were grown in MH broth and subjected to MIC test together with 
the parent strain C. jejuni 81-176. 
Random transposon mutagenesis. C. jejuni 81-176 (JL28 in Table 18) was 
subjected to in vivo transposon mutagenesis using EZ::Tn5™<KAN-2> Transposome 
(Epicentre) as detailed in our previous publication (Lin et al. 2009). Briefly, one 
microliter EZ-Tn5 <KAN-2> TnP transposome complex containing 25 ng transposon 
was used to electroporate C. jejuni JL28 competent cells. The Kanr transformants were 
individually picked and inoculated in 96-well microplates. Following 2 days of 
incubation, cultures of mutants were replicated into microtiter plates containing 4 μg/ml 
of F-1 (2-fold reduction of MIC of the parent strain). Those mutants that could not grow 
in F-1-containing media were selected from the initial plates and subjected to a second 
screening to confirm increased sensitivities of the mutants to F-1. To confirm specific 
genetic linkage between the transposon insertion and increased BCN susceptibility of 
each mutant, backcrossing of the transposon mutations into the parent strain was 
performed using natural transformation (Wang et al. 1990). The MICs of F-1 for the 
backcrossed mutants were determined together with parent strain C. jejuni JL28. The 
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specific transposon insertion site of each mutant was determined by directly sequencing 
the genomic DNA (Lin et al. 2009). Sequence analysis was performed using DNAStar 
software package. 
Targeted mutagenesis of C. jejuni and complementation in trans.  An isogenic 
Cj1583c (designated as sapB) mutant of C. jejuni NCTC 11168 was constructed by 
insertional mutagenesis according to our previous publication (Lin et al. 2005). Briefly, 
approximately 2-kb of the complete Cj1583c was PCR amplified from C. jejuni JL241 
genomic DNA using primer pairs of Cj1583c-R and Cj1583c-F (Table 19) and Taq DNA 
polymerase (Promega). The PCR product was cloned into a pGEM-T Easy vector 
(Promega) to generate pSapB. The chloramphenicol resistance gene cassette (cm) was 
PCR amplified from plasmid pUOA18 (Wang et al. 1990) using PfuUltra® High-Fidelity 
DNA polymerase (Stratagene) and primers of CmF and CmR (Table 19). The resulting 
blunt-ended PCR product was purified and ligated into pSapB vector, which was digested 
with Hind III prior to ligation, to generate the mutant construct pcmSapB (Table 18). The 
construct pcmSapB, which serves as suicide vector, was then introduced into C. jejuni 
JL241 and JL242 by biphasic natural transformation or electroporation (Wang et al. 
1990; Lin et al. 2009). The putative sapB isogenic mutants of corresponding strains were 
selected on MH agar containing 5 μg/ml of Cm. The inactivation of putative sapB 
(Cj1583c) in mutant JL697 was confirmed by PCR (data not shown). 
To complement cjaB mutation in JL657, a 2.7-kb fragment including 174 bp 
upstream of cjaA covering promoter region to 193 bp downstream of cjaB stop codon 
was PCR amplified from NCTC11168 using primer pairs of CjaAB-F and CjaAB-R 
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(Table 19). The PCR was performed using pfu DNA polymerase (Stratagene) and the 
blunt-ended PCR product was purified and ligated to shuttle vector pRY111 (Yao et al. 
1993), which was digested with SmaI prior to ligation. The ligation mix was introduced 
into DH5α by transformation. One transformant (JL690) with a plasmid bearing an intact 
cjaAB operon was created. The pCjaAB from JL690 was then transferred to JL657, a 
cjaB isogenic mutant, by tri-parental conjugation using DH5α/pRK2013 as a helper strain 
(Lin et al. 2005). A similar approach was used to complement tig and cbrR mutations 
using primer pairs of Td-F/Td-R and Cj0643-F/Cj0643-R (Table 19), respectively. The 
insertion of cjaAB, tig, or cbrR sequence in shuttle vector pRY111 was confirmed by 
sequencing using specific primers. 
Prevalence of sap genes among Campylobacter species. To examine the 
prevalence of sapA and sapB in C. jejuni and C. coli, sapA and sapB sequences of 12 
Campylobacter strains in Campylobacter a data bank (CampyDB, 
http://xbase.bham.ac.uk/campydb) were obtained and aligned using the Clustalw 
program. The conserved domains of sapA and sapB were used to design specific primers 
for PCR amplification of sapA and sapB, respectively (Table 19). The primers were used 
to examine the prevalence of sapA and sapB in nineteen Campylobacter strains including 
fifteen C. jejuni strains and four C. coli strains. 
F-1 killing assay. The F-1 killing assay was performed in a 96-well plate as 
described previously (Mount et al. 2010) with minor modifications. Briefly, 
Campylobacter strains were grown in MH broth to mid-log phase, and the cells were 
washed with MH broth and diluted to approximately 106 CFU/ml in MH broth. A volume 
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of 180 μl of the diluted cells was mixed with 20 μl MH broth (control) or F-1 stock (80 
μg/ml) (treatment). The plates were incubated under microaerophilic conditions at 420C 
for 2 hours.  After 2-hour incubation, 20 µl of bacterial culture were taken and serially 
diluted in MH broth and plated onto MH agar plates. The number of CFU was 
enumerated after 2 days of incubation under microaerophilic conditions at 420C. 
Percentage survival was calculated by dividing the CFU of bacteria incubated with F-1 
relative to those incubated in the presence of MH broth and then multiplied by 100. All 
assays were done in triplicate and two independent experiments were performed. The 
significance of differences in susceptibility was determined using the Student’s t-test. 
Chicken colonization experiment. One-day-old broiler chickens were obtained 
from a commercial hatchery (Hubbard Hatchery, Pikesville, TN). The chickens were 
negative for Campylobacter as determined by culturing cloacal swabs prior to use in this 
study. These chickens were randomly assigned into three treatment groups (10 or 11 
chicks/group). At 4 days of age, each chicken was orally inoculated with a 1:1 mixture of 
wild type 81-176 (JL242) and its isogenic cjaB mutant (group I), tig mutant (group II), or 
sapB mutant (group III), with a dose of approximately 107CFU of bacteria per chick. For 
each group, five birds were euthanized and cecal content were collected at 3 and 10 days 
postinoculation (DPI). The cecal content from each bird were weighed and diluted in MH 
broth. The cecal suspensions were duplicate plated onto MH agar plates with 
Campylobacter-specific selective supplements (Oxoid, United Kingdom) for total 
Campylobacter enumeration and onto selective plates supplemented with appropriate 
antibiotics (30 µg/ml of Kan or 6 µg/ml of Cm) for the specific mutant numbers in each 
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sample. The plating media were tested prior to use to ensure that they supported the 
growth of the mutant strains. Notably, before inoculation, the motility of the wild-type 
and its isogenic mutants were confirmed to be at a comparable level. The number of CFU 
per gram of cecal contents was calculated for each chicken and was used as an indicator 
of the colonization level. The detection limit of the plating methods was 100 CFU/g of 
cecal contents. The bird from which no Campylobacter colonies were detected was 
assigned a conservative value of 99 CFU/g of cecal content for the purpose of calculating 
means and for statistical analysis. The significant difference in Campylobacter 
colonization levels (log10 transformed CFU) at each sampling point within group was 
calculated using Student’s t test. A P-value of < 0.01 was considered significant. 
RESULTS 
Susceptibilities of Campylobacter to chicken cathelicidin F-1. As shown in 
Table 20, the majority of C. jejuni and C. coli isolates exhibited susceptibility to chicken 
cathelicidin F-1 with MICs ranging from 4 μg/ml to 8 μg/ml. Only one C. jejuni strain 
showed a slightly higher MIC of 16 μg/ml.  
in vitro selection of F-1 resistant mutants. Different in vitro selection methods 
led to the emergence of F-1 resistant mutants on the selective plates.  A total of 8 mutants 
were selected for MIC testing together with the parent strain 81-176.  However, after 
being cultured in F-1 free MH broth, none of these mutants displayed a higher MIC than 
81-176 for F-1, indicating all these mutants were false-positive. Despite extensive efforts, 
no F-1 resistant mutants were selected in vitro. 
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Identification of genetic loci contributing to F-1 resistance by random 
transposon mutagenesis. A library containing 4,800 Kanr mutants were generated to 
screen for increased susceptibility to F-1. Three mutants displaying increased sensitivity 
to chicken cathelicidin F-1 compared to the parent strain JL28 were identified (Table 21). 
Backcrossing of the transposon mutations into the parent strain by natural transformation 
further confirmed that the F-1-sensitive phenotype in each mutant was linked to the gene 
with a specific transposon insertion. Direct sequencing of the mutant genomic DNA 
using transposon-specific primers revealed a specific transposon insertion site in each 
mutant (Table 21). All the transposon insertions occurred in the coding regions of 
corresponding genes. The orientation of Kanr cassette within the transposon of each 
mutant was the same as the corresponding disrupted gene. 
 F-1 killing assays were further performed to confirm if these three transposon 
mutants displayed higher susceptibility to F-1 than 81-176. As shown in Fig 8A, 
inactivation of CbrR, CjaB, or Tig led to increased susceptibility (5 to 12-fold) to F-1 
compared with their parent strain 81-176. However, only complementation of CjaB 
mutant with wild-type CjaB restored F-1 resistance back to the level of parent strain; 
complementation of CbrR and Tig did not affect F-1 sensitivity of the mutants.  In 
addition, inactivation of CbrR, Tig, or CjaB alone in other strain background (NCTC 
11168 and S3B) also led to increased susceptibilities of the mutants to F-1 (Fig 8B). 
  SapB is required for F-1 resistance in C. jejuni. The sap genes in Haemophilus 
influenza confer AMP resistance in this bacterium (Mason et al. 2005). A BLAST search 
of this study identified genes homologous to the sap genes identified in H. influenza 86-
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028NP (Mason et al. 2005), which include periplasmic solute peptide binding protein 
Cj1584c (25% aa identity to SapA), membrane permease proteins Cj1583c (20% aa 
identity to SapB), Cj1582c (21% identity to SapC). Cj1581c (25% aa identity to SapD), 
and Cj1580c (26% aa identity to SapF). However, the sapZ identified in H. influenza is 
not located on the sap opreron in Campylobacter; the SapZ homolog Cj0999c (32% aa 
identity) was identified in a separate region in C. jejuni NCTC 11168 genome. Isogenic 
SapB mutants were created in C. jejuni 81-176 and NCTC 11168. As shown in Fig 8C, 
inactivation of SapB resulted in increased sensitivity to F-1 (~4-fold) compared with their 
parent strains. 
Two pairs of primers (Sap4-F, Sap4-R) and (Sap5-F, Sap5-F) (Table 19) were 
used to amplify a conserved fragment of sapB and sapA, respectively, in 19 
Campylobacter strains. The PCR survey showed that majority of strains contains sapB 
(17 out of 19) and sapA (15 out of 19) genes. 
Genomic organization of the genes involved in F-1 resistance. As shown in Fig 
7A, cjaB operon consists of two genes cjaA and downstream cjaB (Wyszynska et al. 
2006). The tig operon contains two genes encoding trigger factor (Tig) which may 
function as a chaperon facilitating folding of nascent peptides (Martinez-Hackert et al. 
2009) and an ATP-dependent Clp protease, proteolytic subunit ClpP which was 
demonstrated to be involved in stress tolerance and virulence in Campylobacter and other 
bacteria (Cohn et al. 2007; Frees et al. 2007; Ingmer et al. 2009) (Fig 7B). Sequence 
analysis showed that both trigger factor and ClpP are highly conserved in Campylobacter 
spp (data not shown). The clpP is separated from its downstream gene def by a 28-bp 
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intergenic region which is predicted to contain a promoter sequence 
(http://www.fruitfly.org/seq_tools/promoter.html). Thus, tig operon probably contains 
two genes, trigger factor and clpP. Similarly, genetic organization of the cbrR operon was 
analyzed and presented in Fig 7C. The cbrR operon contains ten genes and the functions 
of the majority of these genes are not understood. The gene cbrR encoding a response 
regulator was demonstrated to be involved in bile salt resistance and in vivo colonization 
in Campylobacter (Raphael et al. 2005). Finally, in Fig 7D, putative sap operon contains 
five genes cj1584c (sapA), cj1583c (sapB), cj1582c (sapC), cj1581c (sapD), and cj1580c 
(sapF). 
Tig, CjaB, and SapB are required for Campylobacter optimal colonization in 
chickens. Since the identified genes confer resistance to F-1 in vitro, it is likely that these 
genes also contribute to colonization of Campylobacter in chicken by mediating 
resistance to F-1. It has been demonstrated that cbrR is required for optimal colonization 
of Campylobacter in chickens (Raphael et al. 2005). Here we examined the role of cjaB, 
tig and sapB in colonization of Campylobacter in chickens. As shown in Fig 9A, B, and 
C, inactivation of cjaB, tig, or sapB greatly impaired the colonization ability of C. jejuni 
81-176 in chickens. Specifically, when the wild-type and its specific isogenic mutant 
were coinoculated into a group of chickens, the colonization level of the specific mutant 
was significantly (P < 0.01) lower than that of the corresponding wild-type strain at 10 
days post-inoculation (DPI). In particular, by 10 DPI, the specific mutant of C. jejuni 81-
176 (tig-, cjaB-, or sapB- mutant) was no longer detected in any of the cecal samples 
collected from the chickens inoculated with a mixture of JL242 and its isogenic mutant. 
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Notably, both the wild-type and its isogenic mutants showed comparable growth patterns 
in MH broth (data not shown). 
DISCUSSION 
Our comprehensive survey using Campylobacter strains demonstrates the potent 
killing activity of F-1 against Campylobacter from various origins and geographically 
diverse regions. The unsuccessful generation of F-1 resistant Campylobacter mutants, 
using cells grown in MH broth that was free of F-1 or containing sublethal concentrations 
of F-1 strongly suggest that it is difficult for Campylobacter to develop acquired 
resistance to chicken host defense peptide F-1. Recently, it has been proposed that AMPs 
exert killing activity via interaction with multiple low-affinity targets. Therefore, 
conceptually it is very difficult for bacteria to develop resistance to AMPs while high-
level resistance to most clinical antibiotics (e.g. fluroquinolone) would be developed 
quickly due to their specific and high affinity target (Peschel et al. 2006). The findings 
from this chapter and the BCN studies in chapter III and IV strongly support this theory 
that bacteria have not developed highly effective mechanisms to resist various AMPs 
during evolution (Peschel et al. 2006). Consequently, either BCNs or endogenous AMPs 
are promising antibiotic alternatives (peptide antibiotics) to control bacterial pathogens. 
Mechanisms of Campylobacter resistance to endogenous defense AMPs are 
largely unknown. Alteration of LOS in the Campylobacter outer membrane led to altered 
susceptibility to the host antimicrobial peptide cathelicidin (Naito et al. 2010; van Mourik 
et al. 2010). In Campylobacter LOS synthesis, two genes gnnA and gnnB facilitate the 
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formation of a 2, 3-diamino-2,3-dideoxy-D-glucose (GlcN3N) disaccharide lipid A 
backbone when compared with the -1-6-linked D-glucosamine (GlcN) disaccharide 
observed in E. coli lipid A. van Mourik et al 2010 demonstrated that inactivation of gnnA 
and gnnB resulted in lipid A alternation and consequently increased sensitivity of the 
mutants to chicken cathelicidin F-1 (van Mourik et al. 2010). Truncation of LOS core in 
different locations resulted in altered sensitivity to human cathelicidin LL-37 (Naito et al. 
2010). 
In this study, inactivation of Campylobacter bile salt resistance regulator (CbrR) 
resulted in increased sensitivity to F-1 and reduced colonization ability in chickens 
(Raphael et al. 2005). However, the CbrR complemented strain did not restore resistance 
back to wild type. Transposon insertion in cbrR may yield polar effects on downstream 
genes. Notably, the gene Cj0649 encodes a beta-barrel OstA protein, known as LptD 
which functions in the assembly of LPS in the outer leaflet of the outer membrane in 
Gram-negative bacteria (Srinivas et al. 2010) and LOS modification in Campylobacter 
altered host cathelicidin susceptibility (Naito et al. 2010; van Mourik et al. 2010). Thus, it 
is likely that LOS synthesis defect may result in increased susceptibility to F-1. 
The gene encoding efflux pump CjaB is widely distributed in Campylobacter 
species and is located downstream of cjaA, and likely these two genes are organized in 
the same operon (Wyszynska et al. 2006). Classification of transporter CjaAB is 
intriguing at this stage (Wyszynska et al. 2006). In this study, we identified 
Campylobacter transporter CjaB that contributes to F-1 resistance in vitro and 
colonization of Campylobacter in chickens. In the chicken digestive tracts, 
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Campylobacter has to interact with multiple antimicrobials and toxic substances 
including chicken antimicrobial peptides (cathelicidin known as fowlicidin, and 
defensins). Using efflux pumps (Lin et al. 2002; Akiba et al. 2006; Lin et al. 2006) to 
extrude toxic compounds is critical for Campylobacter persistence and colonization in 
chickens. At this point, the fowlicidin concentration in chicken intestine and 
comprehensive in vivo information on substrates for the CjaAB efflux transporter are still 
unknown. Thus, a defect in the colonization ability of the Campylobacter CjaB mutant is 
likely the result of multiple actions of other unknown toxic compounds in the digestive 
tract. This speculation needs more studies to identify and characterize the transporter 
CjaAB and its cognate substrates. 
Trigger factor (Tig) was found highly conserved in eubacteria, functioning as a 
chaperon to interact with newly synthesized polypeptides and assist their folding as they 
emerge from the ribosome (Rassow et al. 1996). In Campylobacter, the gene encoding 
trigger factor (Tig) is located upstream of clpP which has proteolytic activity to degrade 
misfolded proteins and plays a critical role in protein quality control in bacteria (Frees et 
al. 2007). Inactivation of Tig by transoposon resulted in increased sensitivity to F-1 in 
Campylobacter. However, complementation of Tig did not restore F-1 resistance back to 
wild type strain, suggesting the tig downstream gene clpP may be indeed responsible for 
F-1 resistance. ClpP mutant resulted in increased sensitivity of Campylobacter to stress 
conditions such as heat and reduced virulence (Cohn et al. 2007). Shauna M. Mc 
Gillivray (ASM 2010 meeting) demonstrated that a ClpP mutant resulted in increased 
sensitivity of Bacillus anthracis to antimicrobialsl, including human cathelicidin LL-37 
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(ASM 2010 meeting). This information strongly suggests the importance of the tig 
operon in F-1 resistance and in vivo colonization of Campylobacter in chickens. It is 
noteworthy that defective colonization of Campylobacter Tig mutant in chickens might 
not be solely the result of increased susceptibility to F-1, but as a consequence of 
increased susceptibility to overall stress conditions in the chicken intestine such as 
temperature, bile salts, and other toxic compounds. 
Our random transposon mutagenesis library (4,800 mutants) was not large enough 
to identify all gene candidates, and thus failed to identify previously known genes 
contributing to fowlicidin resistance such as relevant LOS genes (Naito et al. 2010; van 
Mourik et al. 2010). Bacteria have co-evolved resistance to host AMP and resistance to 
AMP as a combination of multiple components (Peschel et al. 2006). Thus, technical 
limitation of random transposon mutagenesis capable of selecting the mutants with at 
least two fold increased sensitivity could not identify all mutants with mildly increased 
susceptibility (less than two-fold reduction in MIC) to F-1. 
Sap transporters that belong to the ABC-type influx transporter have been 
demonstrated to be required for AMP resistance in various Gram-negative bacteria 
including Salmonella enterica serovar Typhimurium, Proteus mirabilis, Erwinia 
chrysanthemi, and Haemophilus ducreyi (Parra-Lopez et al. 1993; Lopez-Solanilla et al. 
1998; McCoy et al. 2001; Mason et al. 2005; Mount et al. 2010). Inactivation of the Sap 
transporter resulted in defects in colonization in animal models (Lupp et al. 2002; Mason 
et al. 2005; Mason et al. 2006; Mount et al. 2010). However, the Sap transporter does not 
always confer AMP resistance in all bacteria expressing sap genes (Lupp et al. 2002). 
 
 123 
Thus, Sap transporters may display distinct functionality within bacterial species to 
comply with the demands of that particular pathogen. In our study, a homolog to 
SapABCDFZ of non-typeable Haemophilus influenza 86-028NP was identified among 
Campylobacter species. Inactivation of SapB resulted in increased susceptibility to F-1 
(but not to other AMPs such as bacteriocins OR-7, E-760, magainin and cecropin A, 
using MIC tests, data not shown) and caused colonization defects in a chicken model 
system. The gene sapB and sapA were amplified from a majority of Campylobacter 
species including C. jejuni and C. coli. These results suggest the specific functionality of 
Sap transporter in resistance to F-1A and in vivo colonization. The mechanisms of how 
Sap transporters protect the cells from AMP attack are still unknown. It is generally 
believed that AMPs exert bacterial killing activities by inserting cationic peptides into the 
cytoplasmic membrane and form channels that result in leakage of cytoplasmic contents 
(Hancock et al. 2006; Peschel et al. 2006). Because Sap transporters function as influx 
pump, it is likely that Sap transporters reduce AMP localization in the periplasmic space 
by pumping these AMPs into bacterial cytosol and consequently subjecting them to 
enzymatic degradation. More studies to compare the fate of AMP in wild type and 
different sap isogenic mutants could shed light on mechanisms of Sap-mediated 
resistance to different AMPs in Campylobacter. We are currently examining functions of 
each individual sap gene. 
In this study, using F-1 as a model peptide to study chicken AMP resistance in 
Campylobacter, four genes were identified contributing to F-1 resistance. However, at 
this time, there are at least eighteen chicken AMPs (fourteen defensins and four 
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cathelicidins) that have been identified and characterized (Xiao et al. 2006; Lynn et al. 
2007). Thus, more studies are needed to test if these identified genes are also required for 
resistance to other chicken AMPs such as defensins. Taken together, our study provided 
comprehensive information on mechanisms of F-1 resistance in Campylobacter. 
Campylobacter has utilized various strategies in conferring resistance to chicken host 
antimicrobial peptide F-1 to persist and colonize in chickens. Although our results did not 
pinpoint the exact mechanisms which Campylobacter utilizes to resist killing by F-1, the 
information in this study provides a solid foundation to further characterize the 
mechanisms of F-1 resistance in Campylobacter that will help us better understand 
Campylobacter-chicken host interaction and facilitate development of effective measures 













Table 18. Major bacterial strains and plasmids used in this study (Chapter V) 
Strains or 
plasmids Description Source and reference 
C. jejuni 
JL241 NCTC 11168, human isolate (Parkhill et al. 2000) 
JL28 81-176, human isolate, unable  to colonize in 
chicken 
(Black et al. 1988) 
JL242 81-176, human  isolate, can colonize in chickens (Black et al. 1988) 
JL599 JL28 derivative, cbrR::kan This study 
JL628 JL599/pCbrR This study 
JL623 JL241 derivative, cbrR::kan This study 
JL656 JL242 derivative, cbrR::kan This study 
JL601 JL28 derivative, cjaB::kan This study 
JL665 JL241derivative, cjaB::kan This study 
JL657 JL242 derivative, cjaB::kan This study 
JL602 JL28 derivative, tig::kan This study 
JL629 JL241derivative, tig::kan This study 
JL658 JL242 derivative, tig::kan This study 
JL668 JL656/pCbrR  This study 
JL694 JL657/pCjaAB This study 
JL695 JL658/pTig  This study 
JL624 C. jejuni S3B derivative, cbrR::kan This study 
JL631 C. jejuni S3B derivative, tig::kan This study 
JL697 JL242 derivative, cj1583c::cm This study 
JL706 JL241 derivative, cj1583c::cm This study 
Plasmids 
pRY111 E.coli-C.jejuni shuttle vector, Cmr (Yao et al. 1993) 
pCbrR pRY111 containing cbrR This study 
pTig pRY111 containing tig This study 
pCjaAB pRY111 containing cjaAB This study 
pGEM-T Easy Cloning vector, Ampr Promega 
pSapB pGEM-T Easy  containing sapB, Ampr This study 
pcmSapB pSapB with  cm inserted sapB This study 
E.coli    
DH5α F– 80lacZ M15 (lacZYA-argF)U169 recA1 
endA1 hsdR17 (rk–, mk+) phoA supE44 thi-1 gyrA96 
relA1 – 
Invitrogen 
JL690 DH5α  containing pCjaAB operon This study 
JL691 DH5α  containing pTig  This study 
JL652 DH5α  containing pCbrR This study 
JL692 DH5α  containing pGEM-T Easy plus Cj1583c::cm This study 
JL48 Conjugation helper strain, DH5α containing plasmid 
RK2013 




Table 19. Key primers used for PCR in this study (Chapter V) 
Primer DNA Sequence (5’-3’)a Product 
size 
(kb) 





1.6 Trigger factor (tig)  
 Tf-R TGCTATCATTGAAGGCAAATTTTA  
CjaAB-F TCGCCTAATGCCAAAGTTTC 2,7 Complete cjaAB 




Cj0643-F GCAATGCGTATCAACAATCC 1.5 cbrR 
Cj0643-R AAAAATTTCCTTTCTTTTGAAAAC   
 
Cj1583c-F AAAAAGCCGAGGATTTGCTT 2,0 Cj1583c  
 Cj1583c-R CTGTGGCTATAGCATGAACGA  
CmF CGATTTAAATGCTCGGCGGTGTTCCTTT 0.8 cmr cassette 
CmR CGATTTAAATGCGCCCTTTAGTTCCTAAAG  
Sap4-F  GTG CTA AAA CGCTTA GTTTTTAGTATT 0.6 Conserved sapB 
 Sap4-R AATCAAATGCTCTAAACGATTTAA AAA    
Sap5-F GATGCAGTG ATTAATCTTGTATTT TCAGG 0.5 Conserved sapA 




 Table 20.  Susceptibilities of diverse Campylobacter spp. to F-1 
 
Species Number of isolates with MIC of F-1 (µg/ml) Total 
0.5 1 2 4 8 16 174 
        
C. jejuni 0 2 8 58 85 1 154 






Table 21. Mutants with increased sensitivity to F-1 
 






Cj number  
NCTC11168 
Functions or description 
    JL28 8 N/A   
JL602 4 101/1335  Cj0193c Trigger factor (Tig) 
JL599 4 910/1245  Cj0643 Response regulator  (CbrR) 
























Figure 7. Genomic context of cjaB (A), tig (B), cbrR (C), and cj1583c (D). The locations 
of various major primers used in this study are indicated by arrows. The location and 







cbrR tatD pbpC recN cj0653c cj0645 
Kan 
cj1584c cj1583c cj1581c cj1585c nouA 






tig clpP def folE 
Kan 







































































Figure 8. Role of cbrR, tig, cjaB and sapB in F-1 resistance in different C. jejuni strains. 
The F-1 was added to washed bacteria and incubated for 2 hrs at 42oC under 
microaerophic condition. Survival values are relative to original inoculumn (details of 
bacterial strains in Table 18).  (A) Susceptibility of wild-type 81-176 (WT), its cbrR 
(JL656), tig (JL658) and cjaB (JL657) derivative mutants, and their corresponding 
complementation construct JL668, JL695, and JL694 respectively to F-1. (B) Effects of 
mutations in cbrR, tig, and cjaB on the susceptibility of NCTC 11168 and S3B to F-1. 
(C) Inactivation of SapB increased susceptibility of 81-176 and NCTC 11168 to F-1. 
JL697 and JL706 are isogenic SapB mutants of 81-176 and NCTC 11168 respectively. 
Each data represents the mean value obtained from two independent experiments with 





























Figure 9. Inactivation of Tig, CjaB, and SapB reduced C. jejuni 81-176 colonization of 
chickens. Three chicken groups (10 or 11 birds/group) were inoculated with a 1:1 mixture 
of wild type 81-176 and its SapB isogenic mutant (A), CjaB isogenic mutant (B), or Tig 
isogenic mutant (C). For each group, five to six birds were euthanized and the cecal 
contents were collected and used for CFU enumeration at the indicated day 
postinoculation (DPI). Each symbol indicates the log10 number of CFU/g of cecal 
contents for a single chicken. The horizontal bars indicate the means of groups at the 























Campylobacter, commonly found as a commensal organism in the digestive tracts 
of a variety of wild and domestic animals, is a major causative agent of human bacterial 
gastrointestinal diseases in developed countries worldwide (Ruiz-Palacios 2007). Poultry 
are the major reservoir for human Campylobacter infections (Kassenborg et al. 2004). 
Thus, reduction of Campylobacter load in poultry is significant to food safety and public 
health. In particular, at the same time that prevalence of infection is increasing, 
Campylobacter has become increasingly resistant to antibiotics, including 
fluoroquinolones and macrolides, the major drugs of choice for treating human 
campylobacteriosis (Luo et al. 2005), which raises an urgent need for novel intervention 
strategies to prevent and control Campylobacter colonization in poultry (Lin 2009). 
Antimicrobial peptides (AMPs) including bacteriocins (BCNs) are major components of 
host innate immune systems as well as a novel class of antibiotics to control food-borne 
pathogens. Recently, several anti-Campylobacter BCNs and chicken host antimicrobial 
peptide (AMPs) such as fowlicidin-1 have been proposed to control Campylobacter in 
poultry (Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006; Xiao et al. 2006). 
Resistance mechanisms of this pathogen to these AMPs are critical to understand, 
however, largely unknown. In this dissertation research, resistance mechanisms of 
Campylobacter to PM, BCNs, and fowlicidin-1 were studied comprehensively.  
Polymyxin B (PM) has been successfully used as a model to study resistant 
mechanisms of Gram-negative bacteria to host defense AMPs (Ernst et al. 2001; Finlay et 
al. 2004). Inactivation of the genes responsible for PM resistance usually results in 
increased susceptibility of bacteria to a variety of innate AMPs, leading to reduce 
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virulence of the mutants in an animal model system (Ernst et al. 2001). Functional 
genomic studies described in Chapter II successfully identified several genes involved in 
PM resistance in Campylobacter. However, these identified genes did not contribute to 
Campylobacter resistance to other AMPs such as anti-Campylobacter BCNs and chicken 
host defense peptides (F-1, 2). Thus, PM is not an ideal surrogate to study Campylobacter 
resistance to physiologically relevant AMPs. 
Resistance to the promising anti-Campylobacter BCNs was comprehensively 
examined in this dissertation research. Studies in Chapter III and IV demonstrated that 
Campylobacter only developed low-level BCN resistance with low frequency in vitro and 
in vivo. The acquired BCN resistance can be transferred at both inter- and intra-species 
levels. However, BCN resistance is not stable in Campylobacter. Genomic examination 
of two BCN resistant mutants using microarray, random transposon mutagenesis, and 
other functional approaches, revealed that the multidrug efflux pump CmeABC 
contributed to both intrinsic and acquired resistance to BCN (Chapter III). The findings 
from these two chapters support the feasibility of BCN in controlling Campylobacter in 
poultry at the production level, and provide key information for the development of 
effective and sustainable BCNs against Campylobacter infections.  
Campylobacter resistance to F-1, a representative for chicken endogenous AMPs 
was examined in Chapter V. The study in this chapter revealed that Campylobacter spp 
were highly sensitive to F-1 and it was very difficult for Campylobacter to develop 
resistance to F-1 in vitro. Comprehensive examination using random transposon 
mutagenesis, homolog blast search, and site-targeted mutagenesis identified four genes 
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(cbrR, cjaB, tig, and cj1385c) involved in resistance to F-1. These genes were also 
required for optimal colonization of Campylobacter in chickens. The findings from 
Chapter V will not only help us to develop more sustainable peptide antibiotics but also 
provide insights into the delicate host-pathogen interactions and reveal novel intervention 
targets to control Campylobacter infections in humans and animal reservoirs. Together, 
the findings from this dissertation have revealed uniqueness and complexity of AMP 
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